JP5616342B2 - ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 - Google Patents
ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 Download PDFInfo
- Publication number
- JP5616342B2 JP5616342B2 JP2011521823A JP2011521823A JP5616342B2 JP 5616342 B2 JP5616342 B2 JP 5616342B2 JP 2011521823 A JP2011521823 A JP 2011521823A JP 2011521823 A JP2011521823 A JP 2011521823A JP 5616342 B2 JP5616342 B2 JP 5616342B2
- Authority
- JP
- Japan
- Prior art keywords
- reference example
- group
- amino
- chloro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 title claims description 34
- 239000003814 drug Substances 0.000 title claims description 27
- 239000004480 active ingredient Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 322
- 125000004432 carbon atom Chemical group C* 0.000 claims description 58
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 20
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 20
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 20
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 16
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 206010040047 Sepsis Diseases 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 10
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 206010006451 bronchitis Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 208000005333 pulmonary edema Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000002792 vascular Effects 0.000 claims description 9
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 206010014561 Emphysema Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 206010030043 Ocular hypertension Diseases 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 8
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 208000018631 connective tissue disease Diseases 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 8
- 208000030533 eye disease Diseases 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 208000006601 tracheal stenosis Diseases 0.000 claims description 8
- 238000002054 transplantation Methods 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 7
- 206010061323 Optic neuropathy Diseases 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 208000020911 optic nerve disease Diseases 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 6
- 206010050685 Cytokine storm Diseases 0.000 claims description 6
- 208000002927 Hamartoma Diseases 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 6
- 206010062952 diffuse panbronchiolitis Diseases 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 206010051739 Pulmonary sepsis Diseases 0.000 claims description 5
- 230000008602 contraction Effects 0.000 claims description 5
- VRFXYHJTDOEOJN-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C=CC(=C(C1)SC1=CC(=C(C=C1)C(C(CC)CCC)OP(O)(O)=O)Cl)O Chemical compound C(C1=CC=CC=C1)OC=1C=CC(=C(C1)SC1=CC(=C(C=C1)C(C(CC)CCC)OP(O)(O)=O)Cl)O VRFXYHJTDOEOJN-UHFFFAOYSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- ITOWPZSPYKTMDY-QFIPXVFZSA-N [(2s)-2-amino-2-[2-[2-chloro-4-(2-hydroxy-5-propan-2-ylphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(C)C)=CC=C1O ITOWPZSPYKTMDY-QFIPXVFZSA-N 0.000 claims description 3
- VTUOOYPNOCYSRS-QFIPXVFZSA-N [(2s)-2-amino-2-[2-[2-chloro-4-(2-hydroxy-5-propylphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound CCCC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=2)=C1 VTUOOYPNOCYSRS-QFIPXVFZSA-N 0.000 claims description 3
- FOPIBKGBWVNTNP-QFIPXVFZSA-N [(2s)-2-amino-2-[2-[2-chloro-4-(5-cyclopropyl-2-hydroxyphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C2CC2)=CC=C1O FOPIBKGBWVNTNP-QFIPXVFZSA-N 0.000 claims description 3
- WDHXDLFPOPVGGO-IBGZPJMESA-N [(2s)-2-amino-2-[2-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O WDHXDLFPOPVGGO-IBGZPJMESA-N 0.000 claims description 3
- MGQZGOJOLBHWKZ-QHCPKHFHSA-N [(2s)-2-amino-2-[2-[4-(5-tert-butyl-2-hydroxyphenyl)sulfanyl-2-chlorophenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(C)(C)C)=CC=C1O MGQZGOJOLBHWKZ-QHCPKHFHSA-N 0.000 claims description 3
- VCIIPTVDVNHGBE-DEOSSOPVSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O VCIIPTVDVNHGBE-DEOSSOPVSA-N 0.000 claims description 3
- GKNVNNOIQUEFSR-FQEVSTJZSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-propan-2-ylphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CC(C)C1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 GKNVNNOIQUEFSR-FQEVSTJZSA-N 0.000 claims description 3
- XFTACURVQYZXAQ-FQEVSTJZSA-N [(2s)-2-amino-4-[2-chloro-4-(5-cyclopropyl-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC(C2CC2)=CC=C1O XFTACURVQYZXAQ-FQEVSTJZSA-N 0.000 claims description 3
- QLYOIMPVOCSGFK-KRWDZBQOSA-N [(2s)-2-amino-4-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O QLYOIMPVOCSGFK-KRWDZBQOSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims description 2
- ITOWPZSPYKTMDY-UHFFFAOYSA-N [2-amino-2-[2-[2-chloro-4-(2-hydroxy-5-propan-2-ylphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(C)C)=CC=C1O ITOWPZSPYKTMDY-UHFFFAOYSA-N 0.000 claims description 2
- VTUOOYPNOCYSRS-UHFFFAOYSA-N [2-amino-2-[2-[2-chloro-4-(2-hydroxy-5-propylphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound CCCC1=CC=C(O)C(SC=2C=C(Cl)C(CCC(N)(CCC)COP(O)(O)=O)=CC=2)=C1 VTUOOYPNOCYSRS-UHFFFAOYSA-N 0.000 claims description 2
- FOPIBKGBWVNTNP-UHFFFAOYSA-N [2-amino-2-[2-[2-chloro-4-(5-cyclopropyl-2-hydroxyphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C2CC2)=CC=C1O FOPIBKGBWVNTNP-UHFFFAOYSA-N 0.000 claims description 2
- WDHXDLFPOPVGGO-UHFFFAOYSA-N [2-amino-2-[2-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O WDHXDLFPOPVGGO-UHFFFAOYSA-N 0.000 claims description 2
- MGQZGOJOLBHWKZ-UHFFFAOYSA-N [2-amino-2-[2-[4-(5-tert-butyl-2-hydroxyphenyl)sulfanyl-2-chlorophenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(C)(C)C)=CC=C1O MGQZGOJOLBHWKZ-UHFFFAOYSA-N 0.000 claims description 2
- VCIIPTVDVNHGBE-UHFFFAOYSA-N [2-amino-4-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(C)COP(O)(O)=O)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O VCIIPTVDVNHGBE-UHFFFAOYSA-N 0.000 claims description 2
- GKNVNNOIQUEFSR-UHFFFAOYSA-N [2-amino-4-[2-chloro-4-(2-hydroxy-5-propan-2-ylphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CC(C)C1=CC=C(O)C(SC=2C=C(Cl)C(CCC(C)(N)COP(O)(O)=O)=CC=2)=C1 GKNVNNOIQUEFSR-UHFFFAOYSA-N 0.000 claims description 2
- XFTACURVQYZXAQ-UHFFFAOYSA-N [2-amino-4-[2-chloro-4-(5-cyclopropyl-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(C)COP(O)(O)=O)=CC=C1SC1=CC(C2CC2)=CC=C1O XFTACURVQYZXAQ-UHFFFAOYSA-N 0.000 claims description 2
- QLYOIMPVOCSGFK-UHFFFAOYSA-N [2-amino-4-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CCC(N)(C)COP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O QLYOIMPVOCSGFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 2
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 168
- 239000000243 solution Substances 0.000 description 125
- 238000006243 chemical reaction Methods 0.000 description 106
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 239000012230 colorless oil Substances 0.000 description 93
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 69
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 51
- 229910052739 hydrogen Inorganic materials 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 43
- 238000003786 synthesis reaction Methods 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000002904 solvent Substances 0.000 description 41
- 238000000034 method Methods 0.000 description 40
- 229910052757 nitrogen Inorganic materials 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 32
- 239000000843 powder Substances 0.000 description 32
- 238000001816 cooling Methods 0.000 description 29
- 238000001914 filtration Methods 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 230000003287 optical effect Effects 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- -1 cinnamyloxy group Chemical group 0.000 description 21
- 238000000921 elemental analysis Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 239000007810 chemical reaction solvent Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 230000003042 antagnostic effect Effects 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 239000012300 argon atmosphere Substances 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 150000007530 organic bases Chemical class 0.000 description 9
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000012295 chemical reaction liquid Substances 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 8
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 206010047163 Vasospasm Diseases 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- IWXDXDCALKLIKB-UHFFFAOYSA-N tert-butylperoxycarbonyl (2-methylpropan-2-yl)oxy carbonate Chemical compound CC(C)(C)OOC(=O)OC(=O)OOC(C)(C)C IWXDXDCALKLIKB-UHFFFAOYSA-N 0.000 description 5
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 4
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 4
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZVTXBVHMXXIZNA-UHFFFAOYSA-N 4-phenylmethoxy-2-sulfanylphenol Chemical compound C1=C(S)C(O)=CC=C1OCC1=CC=CC=C1 ZVTXBVHMXXIZNA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 101100236683 Homo sapiens MBTPS1 gene Proteins 0.000 description 2
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 150000002941 palladium compounds Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- XHUCVFRMSAASBZ-QVDQXJPCSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-5-propyl-2,5-dihydropyrazine Chemical compound CCCC1N=C(OC)[C@@H](C(C)C)N=C1OC XHUCVFRMSAASBZ-QVDQXJPCSA-N 0.000 description 1
- JJPFXNGOHGFLFK-XLIONFOSSA-N (2r,5r)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-3,6-dimethoxy-2-propan-2-yl-5-prop-2-enyl-2h-pyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@]1(CC=C)CCC1=CC=C(Br)C=C1Cl JJPFXNGOHGFLFK-XLIONFOSSA-N 0.000 description 1
- RLWOWWFVNKMZPU-XLIONFOSSA-N (2r,5s)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-3,6-dimethoxy-2-propan-2-yl-5-propyl-2h-pyrazine Chemical compound C=1C=C(Br)C=C(Cl)C=1CC[C@]1(CCC)N=C(OC)[C@@H](C(C)C)N=C1OC RLWOWWFVNKMZPU-XLIONFOSSA-N 0.000 description 1
- GVZMOYGGPPDITM-QAPCUYQASA-N (2r,5s)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-3,6-dimethoxy-5-methyl-2-propan-2-yl-2h-pyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@]1(C)CCC1=CC=C(Br)C=C1Cl GVZMOYGGPPDITM-QAPCUYQASA-N 0.000 description 1
- KWJTUQJQJMDUJI-NQIIRXRSSA-N (2r,5s)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-5-butyl-3,6-dimethoxy-2-propan-2-yl-2h-pyrazine Chemical compound C=1C=C(Br)C=C(Cl)C=1CC[C@]1(CCCC)N=C(OC)[C@@H](C(C)C)N=C1OC KWJTUQJQJMDUJI-NQIIRXRSSA-N 0.000 description 1
- IQMRUCSKVFCPEP-RDGATRHJSA-N (2r,5s)-5-[2-[2-chloro-4-(2-methoxyphenyl)sulfanylphenyl]ethyl]-3,6-dimethoxy-5-methyl-2-propan-2-yl-2h-pyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@]1(C)CCC(C(=C1)Cl)=CC=C1SC1=CC=CC=C1OC IQMRUCSKVFCPEP-RDGATRHJSA-N 0.000 description 1
- CIBMNIATJHAKEB-RRKGBCIJSA-N (5r)-2-butyl-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazine Chemical compound CCCCC1N=C(OC)[C@@H](C(C)C)N=C1OC CIBMNIATJHAKEB-RRKGBCIJSA-N 0.000 description 1
- AGSVBAIKOLJRNR-BRFYHDHCSA-N (5r)-3,6-dimethoxy-2-methyl-5-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1C AGSVBAIKOLJRNR-BRFYHDHCSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- NLFDUCHXFFKPPW-UHFFFAOYSA-N 1-(methoxymethoxy)-4-methylbenzene Chemical compound COCOC1=CC=C(C)C=C1 NLFDUCHXFFKPPW-UHFFFAOYSA-N 0.000 description 1
- FCNLJRYAEVWSGD-UHFFFAOYSA-N 1-(methoxymethoxy)-4-phenylbenzene Chemical group C1=CC(OCOC)=CC=C1C1=CC=CC=C1 FCNLJRYAEVWSGD-UHFFFAOYSA-N 0.000 description 1
- RCJSNOXRXCAPIW-UHFFFAOYSA-N 1-(methoxymethoxy)-4-propan-2-ylbenzene Chemical compound COCOC1=CC=C(C(C)C)C=C1 RCJSNOXRXCAPIW-UHFFFAOYSA-N 0.000 description 1
- HIXOZCQLIFRETK-UHFFFAOYSA-N 1-(methoxymethoxy)-4-propylbenzene Chemical compound CCCC1=CC=C(OCOC)C=C1 HIXOZCQLIFRETK-UHFFFAOYSA-N 0.000 description 1
- DIWKDNYVEXJOQV-UHFFFAOYSA-N 1-cyclopropyl-4-(methoxymethoxy)benzene Chemical compound C1=CC(OCOC)=CC=C1C1CC1 DIWKDNYVEXJOQV-UHFFFAOYSA-N 0.000 description 1
- ZBLFCWKVDYDWIY-UHFFFAOYSA-N 1-ethyl-4-(methoxymethoxy)benzene Chemical compound CCC1=CC=C(OCOC)C=C1 ZBLFCWKVDYDWIY-UHFFFAOYSA-N 0.000 description 1
- KOUFOLRRYLERAE-UHFFFAOYSA-N 1-tert-butyl-4-(methoxymethoxy)benzene Chemical compound COCOC1=CC=C(C(C)(C)C)C=C1 KOUFOLRRYLERAE-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- UVJATRCNVCESJN-UHFFFAOYSA-N 2-(methoxymethoxy)-5-methylbenzenethiol Chemical compound COCOC1=CC=C(C)C=C1S UVJATRCNVCESJN-UHFFFAOYSA-N 0.000 description 1
- ZGHSTPXSFHMQOC-UHFFFAOYSA-N 2-(methoxymethoxy)-5-phenylbenzenethiol Chemical compound C1=C(S)C(OCOC)=CC=C1C1=CC=CC=C1 ZGHSTPXSFHMQOC-UHFFFAOYSA-N 0.000 description 1
- CRORDSVFCYNKIX-UHFFFAOYSA-N 2-(methoxymethoxy)-5-propan-2-ylbenzenethiol Chemical compound COCOC1=CC=C(C(C)C)C=C1S CRORDSVFCYNKIX-UHFFFAOYSA-N 0.000 description 1
- MJHMGJCWEQKDMD-UHFFFAOYSA-N 2-(methoxymethoxy)-5-propylbenzenethiol Chemical compound CCCC1=CC=C(OCOC)C(S)=C1 MJHMGJCWEQKDMD-UHFFFAOYSA-N 0.000 description 1
- DSCJETUEDFKYGN-UHFFFAOYSA-N 2-Methoxybenzenethiol Chemical compound COC1=CC=CC=C1S DSCJETUEDFKYGN-UHFFFAOYSA-N 0.000 description 1
- RLEOFLJQKJCQOE-UHFFFAOYSA-N 2-[2-chloro-4-(2-methoxyphenyl)sulfanylphenyl]acetaldehyde Chemical compound COC1=CC=CC=C1SC1=CC=C(CC=O)C(Cl)=C1 RLEOFLJQKJCQOE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BHFZOAZGYOLYIY-UHFFFAOYSA-N 2-chloro-1-(2-iodoethyl)-4-(2-methoxyphenyl)sulfanylbenzene Chemical compound COC1=CC=CC=C1SC1=CC=C(CCI)C(Cl)=C1 BHFZOAZGYOLYIY-UHFFFAOYSA-N 0.000 description 1
- SLWXGMHZJLITHD-UHFFFAOYSA-N 2-chloro-4-(2-methoxyphenyl)sulfanylbenzaldehyde Chemical compound COC1=CC=CC=C1SC1=CC=C(C=O)C(Cl)=C1 SLWXGMHZJLITHD-UHFFFAOYSA-N 0.000 description 1
- KMQWNQKESAHDKD-UHFFFAOYSA-N 2-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Cl)=C1 KMQWNQKESAHDKD-UHFFFAOYSA-N 0.000 description 1
- RKUSRLUGUVDNKP-UHFFFAOYSA-N 2-methoxy-5-(trifluoromethyl)aniline Chemical compound COC1=CC=C(C(F)(F)F)C=C1N RKUSRLUGUVDNKP-UHFFFAOYSA-N 0.000 description 1
- UHEUPPZSYHEVFI-UHFFFAOYSA-N 2-methoxy-5-(trifluoromethyl)benzenethiol Chemical compound COC1=CC=C(C(F)(F)F)C=C1S UHEUPPZSYHEVFI-UHFFFAOYSA-N 0.000 description 1
- WGHBYJWHKZTOTC-FQEVSTJZSA-N 3-[4-[(3s)-3-amino-3-(phosphonooxymethyl)hexyl]-3-chlorophenyl]sulfanyl-4-hydroxybenzoic acid Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(O)=O)=CC=C1O WGHBYJWHKZTOTC-FQEVSTJZSA-N 0.000 description 1
- KLSLBUSXWBJMEC-UHFFFAOYSA-N 4-Propylphenol Chemical compound CCCC1=CC=C(O)C=C1 KLSLBUSXWBJMEC-UHFFFAOYSA-N 0.000 description 1
- HJFGRXXBCDISJZ-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxy-2-sulfanylphenol Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C(O)C(S)=C1 HJFGRXXBCDISJZ-UHFFFAOYSA-N 0.000 description 1
- FYOIKHJHYDLNJY-UHFFFAOYSA-N 4-bromo-2-chloro-1-(2-iodoethyl)benzene Chemical compound ClC1=CC(Br)=CC=C1CCI FYOIKHJHYDLNJY-UHFFFAOYSA-N 0.000 description 1
- IGIWPHRUBXKMAR-UHFFFAOYSA-N 4-cyclopropylphenol Chemical compound C1=CC(O)=CC=C1C1CC1 IGIWPHRUBXKMAR-UHFFFAOYSA-N 0.000 description 1
- CGMJYWDBLOFABI-UHFFFAOYSA-N 4-ethoxy-2-sulfanylphenol Chemical compound CCOC1=CC=C(O)C(S)=C1 CGMJYWDBLOFABI-UHFFFAOYSA-N 0.000 description 1
- SZPLALNDBUAMJG-UHFFFAOYSA-N 4-methoxy-2-sulfanylphenol Chemical compound COC1=CC=C(O)C(S)=C1 SZPLALNDBUAMJG-UHFFFAOYSA-N 0.000 description 1
- ZBOFKBOCEFAYDD-UHFFFAOYSA-N 4-propan-2-yloxy-2-sulfanylphenol Chemical compound CC(C)OC1=CC=C(O)C(S)=C1 ZBOFKBOCEFAYDD-UHFFFAOYSA-N 0.000 description 1
- YNNXBGVXIHSTCN-UHFFFAOYSA-N 5-chloro-2-methoxybenzenethiol Chemical compound COC1=CC=C(Cl)C=C1S YNNXBGVXIHSTCN-UHFFFAOYSA-N 0.000 description 1
- UEHCOZQUSPJNRV-UHFFFAOYSA-N 5-cyclopropyl-2-(methoxymethoxy)benzenethiol Chemical compound C1=C(S)C(OCOC)=CC=C1C1CC1 UEHCOZQUSPJNRV-UHFFFAOYSA-N 0.000 description 1
- GTRPPLMNYAPEMP-UHFFFAOYSA-N 5-ethyl-2-(methoxymethoxy)benzenethiol Chemical compound CCC1=CC=C(OCOC)C(S)=C1 GTRPPLMNYAPEMP-UHFFFAOYSA-N 0.000 description 1
- FCCIWWYZBFTHQY-UHFFFAOYSA-N 5-tert-butyl-2-(methoxymethoxy)benzenethiol Chemical compound COCOC1=CC=C(C(C)(C)C)C=C1S FCCIWWYZBFTHQY-UHFFFAOYSA-N 0.000 description 1
- VOYXPVUWCDXOGX-UHFFFAOYSA-N 6-[tert-butyl(dimethyl)silyl]oxy-1,3-benzoxathiol-2-one Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C2SC(=O)OC2=C1 VOYXPVUWCDXOGX-UHFFFAOYSA-N 0.000 description 1
- MPJLMJRVYTZZCU-UHFFFAOYSA-N 6-ethoxy-1,3-benzoxathiol-2-one Chemical compound CCOC1=CC=C2SC(=O)OC2=C1 MPJLMJRVYTZZCU-UHFFFAOYSA-N 0.000 description 1
- BQRBHTGETAIXFD-UHFFFAOYSA-N 6-propan-2-yloxy-1,3-benzoxathiol-2-one Chemical compound CC(C)OC1=CC=C2SC(=O)OC2=C1 BQRBHTGETAIXFD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010058040 Abdominal sepsis Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 description 1
- 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ORZRPWUHANPVLX-SANMLTNESA-N [(2s)-2-amino-2-[2-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O ORZRPWUHANPVLX-SANMLTNESA-N 0.000 description 1
- WFYJBVMHQUKLCN-FQEVSTJZSA-N [(2s)-2-amino-2-[2-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]ethyl]hexyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCCC)COP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O WFYJBVMHQUKLCN-FQEVSTJZSA-N 0.000 description 1
- NCPHLNFTSQMTBO-SFHVURJKSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-methoxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound COC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 NCPHLNFTSQMTBO-SFHVURJKSA-N 0.000 description 1
- MRRJOQTUZXUVLX-SFHVURJKSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-methylphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 MRRJOQTUZXUVLX-SFHVURJKSA-N 0.000 description 1
- JZNHSWWXQGDMGP-FQEVSTJZSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-propan-2-yloxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CC(C)OC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 JZNHSWWXQGDMGP-FQEVSTJZSA-N 0.000 description 1
- ZQJFCZHRZXPVQH-FQEVSTJZSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxy-5-propylphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CCCC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 ZQJFCZHRZXPVQH-FQEVSTJZSA-N 0.000 description 1
- BABJEVROIDFGGG-KRWDZBQOSA-N [(2s)-2-amino-4-[2-chloro-4-(2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC=CC=C1O BABJEVROIDFGGG-KRWDZBQOSA-N 0.000 description 1
- LKOWNRDOOZXNLQ-KRWDZBQOSA-N [(2s)-2-amino-4-[2-chloro-4-(5-chloro-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC(Cl)=CC=C1O LKOWNRDOOZXNLQ-KRWDZBQOSA-N 0.000 description 1
- VFIBKQVPTWHGIH-SFHVURJKSA-N [(2s)-2-amino-4-[2-chloro-4-(5-cyano-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(C)COP(O)(O)=O)=CC=C1SC1=CC(C#N)=CC=C1O VFIBKQVPTWHGIH-SFHVURJKSA-N 0.000 description 1
- ZSDTXJVNESOTLS-IBGZPJMESA-N [(2s)-2-amino-4-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CCOC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 ZSDTXJVNESOTLS-IBGZPJMESA-N 0.000 description 1
- WYUIZXIMYHFYDX-IBGZPJMESA-N [(2s)-2-amino-4-[2-chloro-4-(5-ethyl-2-hydroxyphenyl)sulfanylphenyl]-2-methylbutyl] dihydrogen phosphate Chemical compound CCC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 WYUIZXIMYHFYDX-IBGZPJMESA-N 0.000 description 1
- ZHXUQAKHSHKCJZ-IBGZPJMESA-N [(2s)-4-[4-(5-acetyl-2-hydroxyphenyl)sulfanyl-2-chlorophenyl]-2-amino-2-methylbutyl] dihydrogen phosphate Chemical compound CC(=O)C1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@](C)(N)COP(O)(O)=O)=CC=2)=C1 ZHXUQAKHSHKCJZ-IBGZPJMESA-N 0.000 description 1
- ZOERVRIYPSJUOH-FQEVSTJZSA-N [(3s)-3-amino-3-[2-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]ethyl]hexyl]phosphonic acid Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)CCP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O ZOERVRIYPSJUOH-FQEVSTJZSA-N 0.000 description 1
- GSGXXXNACJPPJQ-SFHVURJKSA-N [(3s)-3-amino-5-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-methylpentyl]phosphonic acid Chemical compound C1=C(Cl)C(CC[C@@](N)(C)CCP(O)(O)=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O GSGXXXNACJPPJQ-SFHVURJKSA-N 0.000 description 1
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 1
- NDJSVGPNLHLSTF-DEOSSOPVSA-N [3-[3-chloro-4-[(3s)-4-hydroxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanyl-4-(methoxymethoxy)phenyl] trifluoromethanesulfonate Chemical compound COCOC1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 NDJSVGPNLHLSTF-DEOSSOPVSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- NOXYEXFQXDRHTA-UHFFFAOYSA-N [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 Chemical compound [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 NOXYEXFQXDRHTA-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- WGZCUXZFISUUPR-UHFFFAOYSA-N acetonitrile;oxolane Chemical compound CC#N.C1CCOC1 WGZCUXZFISUUPR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- XAVFZUKFLWOSOS-UHFFFAOYSA-N bis(dimethoxyphosphoryl)methane Chemical compound COP(=O)(OC)CP(=O)(OC)OC XAVFZUKFLWOSOS-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- PPTSBERGOGHCHC-UHFFFAOYSA-N boron lithium Chemical compound [Li].[B] PPTSBERGOGHCHC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001218 inhibitory effect on sepsis Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- NCPHGZWGGANCAY-UHFFFAOYSA-N methane;ruthenium Chemical compound C.[Ru] NCPHGZWGGANCAY-UHFFFAOYSA-N 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- LVTKHVWWQDSADG-IBGZPJMESA-N methyl (2s)-2-[2-(4-bromo-2-chlorophenyl)ethyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC(C)(C)OC(=O)N[C@@](C(=O)OC)(CCC)CCC1=CC=C(Br)C=C1Cl LVTKHVWWQDSADG-IBGZPJMESA-N 0.000 description 1
- QCRFVARLYDGGOQ-KRWDZBQOSA-N methyl (2s)-4-(4-bromo-2-chlorophenyl)-2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@](C)(C(=O)OC)CCC1=CC=C(Br)C=C1Cl QCRFVARLYDGGOQ-KRWDZBQOSA-N 0.000 description 1
- GQAXOYYGMARRPV-DEOSSOPVSA-N methyl (2s)-4-[2-chloro-4-(2-methoxyphenyl)sulfanylphenyl]-2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound C1=C(Cl)C(CC[C@@](C)(C(=O)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC=CC=C1OC GQAXOYYGMARRPV-DEOSSOPVSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- DDMZELRHGRYJKK-UHFFFAOYSA-N o-ethyl [2-methoxy-5-(trifluoromethyl)phenyl]sulfanylmethanethioate Chemical compound CCOC(=S)SC1=CC(C(F)(F)F)=CC=C1OC DDMZELRHGRYJKK-UHFFFAOYSA-N 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003409 sphingosine 1-phosphates Chemical class 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KZGGIYQJTFZJBQ-MHZLTWQESA-N tert-butyl N-[(3S)-5-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-1-dimethoxyphosphoryl-3-methylpent-1-en-3-yl]carbamate Chemical compound C(C)(C)(C)OC(=O)N[C@](C=CP(OC)(OC)=O)(CCC1=C(C=C(C=C1)SC1=C(C=CC(=C1)C(F)(F)F)OCOC)Cl)C KZGGIYQJTFZJBQ-MHZLTWQESA-N 0.000 description 1
- YCUULVLQFZCOLX-YTTGMZPUSA-N tert-butyl [2-[3-chloro-4-[(3s)-3-(dimethoxyphosphoryloxymethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]heptyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](CCCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C YCUULVLQFZCOLX-YTTGMZPUSA-N 0.000 description 1
- UJDRYEVTBFKFRZ-HKBQPEDESA-N tert-butyl [2-[3-chloro-4-[(3s)-3-(dimethoxyphosphoryloxymethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C UJDRYEVTBFKFRZ-HKBQPEDESA-N 0.000 description 1
- MTWQQYDTGXLEMM-PMERELPUSA-N tert-butyl [2-[3-chloro-4-[(3s)-3-(hydroxymethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]heptyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C MTWQQYDTGXLEMM-PMERELPUSA-N 0.000 description 1
- QZXDUBOPKGBBMN-LJAQVGFWSA-N tert-butyl [2-[3-chloro-4-[(3s)-3-(hydroxymethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C QZXDUBOPKGBBMN-LJAQVGFWSA-N 0.000 description 1
- BDCIEACNTJNNSW-LJAQVGFWSA-N tert-butyl [2-[3-chloro-4-[(3s)-4-dimethoxyphosphoryloxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C BDCIEACNTJNNSW-LJAQVGFWSA-N 0.000 description 1
- NPEDIQWGPMFUCU-LJAQVGFWSA-N tert-butyl [2-[3-chloro-4-[(3s)-4-dimethoxyphosphoryloxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanylphenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC=CC=C1OC(=O)OC(C)(C)C NPEDIQWGPMFUCU-LJAQVGFWSA-N 0.000 description 1
- PZOMEWWMWMAQTA-MHZLTWQESA-N tert-butyl [2-[3-chloro-4-[(3s)-4-hydroxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanyl-4-(trifluoromethyl)phenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC(=O)OC(C)(C)C PZOMEWWMWMAQTA-MHZLTWQESA-N 0.000 description 1
- JKOBZDMMQWMRQE-LJAQVGFWSA-N tert-butyl [4-chloro-2-[3-chloro-4-[(3s)-4-dimethoxyphosphoryloxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanylphenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(Cl)=CC=C1OC(=O)OC(C)(C)C JKOBZDMMQWMRQE-LJAQVGFWSA-N 0.000 description 1
- VOMGDKQNBFJCEX-MHZLTWQESA-N tert-butyl [4-chloro-2-[3-chloro-4-[(3s)-4-hydroxy-3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]phenyl]sulfanylphenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(Cl)=CC=C1OC(=O)OC(C)(C)C VOMGDKQNBFJCEX-MHZLTWQESA-N 0.000 description 1
- YJHQXYAISHPJGU-INIZCTEOSA-N tert-butyl n-[(2s)-4-(4-bromo-2-chlorophenyl)-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@](C)(CO)CCC1=CC=C(Br)C=C1Cl YJHQXYAISHPJGU-INIZCTEOSA-N 0.000 description 1
- ASMBDZQRNPNMAF-VWLOTQADSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-methoxyphenyl)sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=2)=C1 ASMBDZQRNPNMAF-VWLOTQADSA-N 0.000 description 1
- VTLWCZMYKMEEET-QHCPKHFHSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-methoxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=2)=C1 VTLWCZMYKMEEET-QHCPKHFHSA-N 0.000 description 1
- MNVHCLRDUFDFPK-HKBQPEDESA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O MNVHCLRDUFDFPK-HKBQPEDESA-N 0.000 description 1
- WCXUWMCFTASYBB-LJAQVGFWSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O WCXUWMCFTASYBB-LJAQVGFWSA-N 0.000 description 1
- RPZPXRSWTPDUBL-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-propan-2-yloxyphenyl)sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OC(C)C)=CC=C1O RPZPXRSWTPDUBL-MHZLTWQESA-N 0.000 description 1
- OVFZOPPCLVQOQK-VWLOTQADSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-hydroxy-5-propan-2-yloxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound CC(C)OC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=2)=C1 OVFZOPPCLVQOQK-VWLOTQADSA-N 0.000 description 1
- UPUWPMFGPGTIFZ-QHCPKHFHSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(2-methoxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COC1=CC=CC=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 UPUWPMFGPGTIFZ-QHCPKHFHSA-N 0.000 description 1
- RWVVZZKGLRWTDY-QHCPKHFHSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(5-chloro-2-methoxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COC1=CC=C(Cl)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 RWVVZZKGLRWTDY-QHCPKHFHSA-N 0.000 description 1
- JROOOKMDFQUTEI-SANMLTNESA-N tert-butyl n-[(2s)-4-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound CCOC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=2)=C1 JROOOKMDFQUTEI-SANMLTNESA-N 0.000 description 1
- WFDYOTUACJZXNI-DEOSSOPVSA-N tert-butyl n-[(2s)-4-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound CCOC1=CC=C(O)C(SC=2C=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=2)=C1 WFDYOTUACJZXNI-DEOSSOPVSA-N 0.000 description 1
- JUWFHZCYGKHCSL-DEOSSOPVSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(F)(F)F)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 JUWFHZCYGKHCSL-DEOSSOPVSA-N 0.000 description 1
- QHUUAGFZKWYCCF-DEOSSOPVSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-2-methyl-1-oxobutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(F)(F)F)C=C1SC1=CC=C(CC[C@](C)(NC(=O)OC(C)(C)C)C=O)C(Cl)=C1 QHUUAGFZKWYCCF-DEOSSOPVSA-N 0.000 description 1
- CFYHEBATRUDREW-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-methylphenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C)C=C1SC1=CC=C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 CFYHEBATRUDREW-MHZLTWQESA-N 0.000 description 1
- HJXMYLAZASJFBD-VWLOTQADSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-methylphenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 HJXMYLAZASJFBD-VWLOTQADSA-N 0.000 description 1
- IAJIEGGQGUYSJV-LJAQVGFWSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-propan-2-ylphenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(C)C)C=C1SC1=CC=C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 IAJIEGGQGUYSJV-LJAQVGFWSA-N 0.000 description 1
- WQANSEWMPJFQSK-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-propan-2-ylphenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(C)C)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 WQANSEWMPJFQSK-MHZLTWQESA-N 0.000 description 1
- YGFVZTRJHYRVRC-LJAQVGFWSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-propylphenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound CCCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=2)=C1 YGFVZTRJHYRVRC-LJAQVGFWSA-N 0.000 description 1
- AVJQTEFUEXOPOF-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-(methoxymethoxy)-5-propylphenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound CCCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=2)=C1 AVJQTEFUEXOPOF-MHZLTWQESA-N 0.000 description 1
- MGWGYOIFAYZDFV-QFIPXVFZSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O MGWGYOIFAYZDFV-QFIPXVFZSA-N 0.000 description 1
- CXTNNKYEFLIOHL-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-cyano-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C#N)C=C1SC1=CC=C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 CXTNNKYEFLIOHL-MHZLTWQESA-N 0.000 description 1
- MSXKTZIFBPRMNQ-VWLOTQADSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-cyano-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C#N)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 MSXKTZIFBPRMNQ-VWLOTQADSA-N 0.000 description 1
- NTIWMJQDIWMXPI-LJAQVGFWSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-cyclopropyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C2CC2)C=C1SC1=CC=C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 NTIWMJQDIWMXPI-LJAQVGFWSA-N 0.000 description 1
- BONRZJXMMGHBOW-MHZLTWQESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-cyclopropyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C2CC2)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 BONRZJXMMGHBOW-MHZLTWQESA-N 0.000 description 1
- CRBZJJNFESCXNO-NDEPHWFRSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-ethyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound CCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=2)=C1 CRBZJJNFESCXNO-NDEPHWFRSA-N 0.000 description 1
- ROMJTIRPTNQPRN-SANMLTNESA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-ethyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound CCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=2)=C1 ROMJTIRPTNQPRN-SANMLTNESA-N 0.000 description 1
- WWBINWDQVWLKIW-DEOSSOPVSA-N tert-butyl n-[(2s)-4-[2-chloro-4-[5-hydroxy-2-(methoxymethoxy)phenyl]sulfanylphenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(O)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 WWBINWDQVWLKIW-DEOSSOPVSA-N 0.000 description 1
- VLIGSCLRECKGLW-PMERELPUSA-N tert-butyl n-[(2s)-4-[4-[5-[tert-butyl(dimethyl)silyl]oxy-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 VLIGSCLRECKGLW-PMERELPUSA-N 0.000 description 1
- AUMSUYKCFDQZHW-NDEPHWFRSA-N tert-butyl n-[(2s)-4-[4-[5-[tert-butyl(dimethyl)silyl]oxy-2-hydroxyphenyl]sulfanyl-2-chlorophenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(O[Si](C)(C)C(C)(C)C)=CC=C1O AUMSUYKCFDQZHW-NDEPHWFRSA-N 0.000 description 1
- NAYLFHLSAQLVAK-NDEPHWFRSA-N tert-butyl n-[(2s)-4-[4-[5-acetyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-1-dimethoxyphosphoryloxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(C)=O)C=C1SC1=CC=C(CC[C@@](C)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 NAYLFHLSAQLVAK-NDEPHWFRSA-N 0.000 description 1
- MSHWDSWBUGPKOB-SANMLTNESA-N tert-butyl n-[(2s)-4-[4-[5-acetyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-1-hydroxy-2-methylbutan-2-yl]carbamate Chemical compound COCOC1=CC=C(C(C)=O)C=C1SC1=CC=C(CC[C@@](C)(CO)NC(=O)OC(C)(C)C)C(Cl)=C1 MSHWDSWBUGPKOB-SANMLTNESA-N 0.000 description 1
- OUYIWHPJPPZWPC-SFHVURJKSA-N tert-butyl n-[(3r)-1-(4-bromo-2-chlorophenyl)-3-(hydroxymethyl)hex-5-en-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](CO)(CC=C)CCC1=CC=C(Br)C=C1Cl OUYIWHPJPPZWPC-SFHVURJKSA-N 0.000 description 1
- SGQDWWBGCJFEPT-IBGZPJMESA-N tert-butyl n-[(3s)-1-(4-bromo-2-chlorophenyl)-3-(hydroxymethyl)heptan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](CO)(CCCC)CCC1=CC=C(Br)C=C1Cl SGQDWWBGCJFEPT-IBGZPJMESA-N 0.000 description 1
- RNRAWWOXWRNDFG-SFHVURJKSA-N tert-butyl n-[(3s)-1-(4-bromo-2-chlorophenyl)-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](CO)(CCC)CCC1=CC=C(Br)C=C1Cl RNRAWWOXWRNDFG-SFHVURJKSA-N 0.000 description 1
- CVUZJZKGPRLMGX-XIFFEERXSA-N tert-butyl n-[(3s)-1-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O CVUZJZKGPRLMGX-XIFFEERXSA-N 0.000 description 1
- NOTAAYNQODFSIM-HKBQPEDESA-N tert-butyl n-[(3s)-1-[2-chloro-4-(2-hydroxy-5-phenylmethoxyphenyl)sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC=2C=CC=CC=2)=CC=C1O NOTAAYNQODFSIM-HKBQPEDESA-N 0.000 description 1
- KHIIPTCKFAYMBZ-LJAQVGFWSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-(2-dimethoxyphosphorylethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(CCP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCOC KHIIPTCKFAYMBZ-LJAQVGFWSA-N 0.000 description 1
- OFQWMFPYJTVRTF-SANMLTNESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCOC OFQWMFPYJTVRTF-SANMLTNESA-N 0.000 description 1
- QWERLTNGIQTSTL-SANMLTNESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-formylhexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CCC)(NC(=O)OC(C)(C)C)C=O)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCOC QWERLTNGIQTSTL-SANMLTNESA-N 0.000 description 1
- DKFJVZYZEYLTNJ-MHZLTWQESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]-5-dimethoxyphosphoryl-3-methylpentan-3-yl]carbamate Chemical compound COCOC1=CC=C(C(F)(F)F)C=C1SC1=CC=C(CC[C@@](C)(CCP(=O)(OC)OC)NC(=O)OC(C)(C)C)C(Cl)=C1 DKFJVZYZEYLTNJ-MHZLTWQESA-N 0.000 description 1
- HNKFJEAGRCNSJB-HKBQPEDESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-propan-2-ylphenyl]sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)C)=CC=C1OCOC HNKFJEAGRCNSJB-HKBQPEDESA-N 0.000 description 1
- GGWVHAYQHYRKJM-LJAQVGFWSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-propan-2-ylphenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)C)=CC=C1OCOC GGWVHAYQHYRKJM-LJAQVGFWSA-N 0.000 description 1
- KOPWAIWOBFKSED-HKBQPEDESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-propylphenyl]sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound CCCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=2)=C1 KOPWAIWOBFKSED-HKBQPEDESA-N 0.000 description 1
- JDODTOPBKBBZPL-LJAQVGFWSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-(methoxymethoxy)-5-propylphenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound CCCC1=CC=C(OCOC)C(SC=2C=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=2)=C1 JDODTOPBKBBZPL-LJAQVGFWSA-N 0.000 description 1
- XNWZVNIPOMXVOB-DEOSSOPVSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-hydroxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1O XNWZVNIPOMXVOB-DEOSSOPVSA-N 0.000 description 1
- LGEPVKSQGFAIHT-SANMLTNESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-methoxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)heptan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC LGEPVKSQGFAIHT-SANMLTNESA-N 0.000 description 1
- JXMLKBHCZVZHCC-VWLOTQADSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[2-methoxy-5-(trifluoromethyl)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OC JXMLKBHCZVZHCC-VWLOTQADSA-N 0.000 description 1
- CWBRZGABOCCGDE-HKBQPEDESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-cyclopropyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C2CC2)=CC=C1OCOC CWBRZGABOCCGDE-HKBQPEDESA-N 0.000 description 1
- JTRCYOUYGPIXFN-LJAQVGFWSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-cyclopropyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C2CC2)=CC=C1OCOC JTRCYOUYGPIXFN-LJAQVGFWSA-N 0.000 description 1
- NWCSFNVNNRWXCN-YTTGMZPUSA-N tert-butyl n-[(3s)-1-[4-[5-tert-butyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)(C)C)=CC=C1OCOC NWCSFNVNNRWXCN-YTTGMZPUSA-N 0.000 description 1
- LXVVTBVZUICSMS-PMERELPUSA-N tert-butyl n-[(3s)-1-[4-[5-tert-butyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)(C)C)=CC=C1OCOC LXVVTBVZUICSMS-PMERELPUSA-N 0.000 description 1
- HFGRNDZMSOZHQU-LJAQVGFWSA-N tert-butyl n-[(3s)-3-[2-[2-chloro-4-[2-(methoxymethoxy)-5-(trifluoromethyl)phenyl]sulfanylphenyl]ethyl]-1-dimethoxyphosphorylhex-1-en-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CCC)(NC(=O)OC(C)(C)C)C=CP(=O)(OC)OC)=CC=C1SC1=CC(C(F)(F)F)=CC=C1OCOC HFGRNDZMSOZHQU-LJAQVGFWSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
一般式(1)
また、第2発明は、前記一般式(1)で表される化合物が、一般式(1a)
また、第3発明は、前記一般式(1)で表される化合物が、一般式(1b)
また、第4発明は、前記一般式(1)で表される化合物が、一般式(1c)
また、第5発明は、前記R1がトリフルオロメチル基、炭素数1〜6のアルキル基、炭素数3〜6のシクロアルキル基、炭素数6〜10のアリール基又はベンジルオキシ基である第4発明記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第6発明は、前記一般式(1)で示される化合物が、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(R)−2−アリル−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−プロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[4−(5−t−ブチル−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−ビフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、又は
(S)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステルである第1発明記載のジフェニルスルフィド誘導体、若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第7発明は、前記一般式(1)で示される化合物が、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アリル−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−プロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[4−(5−t−ブチル−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−ビフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、又は
(−)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステルである第1発明記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第8の発明は、第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物を有効成分とするスフィンゴシン−1−リン酸3(S1P3)レセプターアンタゴニスト作用に基づく医薬、に関する。
また、第9発明は、気道収縮、気管支喘息、慢性閉塞性肺疾患(COPD)、肺気腫、気管狭窄症、びまん性汎細気管支炎、感染、結合組織病もしくは移植に伴う気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、敗血症またはインフルエンザウイルスもしくはRSウイルス感染に基づくサイトカインストームの治療又は予防薬である第8発明記載の医薬に関する。
また、第10発明は、動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症または心筋梗塞、糸球体腎炎、血栓症、肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の治療薬である第8発明記載の医薬に関する。
また、第11発明は、敗血症の治療又は予防薬である第8発明記載の医薬に関する。
また、第12発明は、第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物及び薬理学的に許容されうる担体を含有する医薬組成物、に関する。
また、第13発明は、S1P3レセプターアンタゴニスト作用に基づく医薬の製造における、第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物の使用に関する。
また、第14発明は、S1P3レセプターアンタゴニスト作用に基づく医薬が、気道収縮、気管支喘息、慢性閉塞性肺疾患(COPD)、肺気腫、気管狭窄症、びまん性汎細気管支炎、感染、結合組織病もしくは移植に伴う気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、敗血症またはインフルエンザウイルスもしくはRSウイルス感染に基づくサイトカインストームの治療又は予防薬である第13発明記載の使用に関する。
また、第15発明は、S1P3レセプターアンタゴニスト作用に基づく医薬が、動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症または心筋梗塞、糸球体腎炎、血栓症、肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の治療薬である第13発明記載の使用に関する。
また、第16発明は、S1P3レセプターアンタゴニスト作用に基づく医薬が、敗血症の治療又は予防薬である第13発明記載の使用に関する。
また、第17発明は、S1P3レセプターアンタゴニスト作用の誘発における使用のための、第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第18発明は、気道収縮、気管支喘息、慢性閉塞性肺疾患(COPD)、肺気腫、気管狭窄症、びまん性汎細気管支炎、感染、結合組織病もしくは移植に伴う気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、敗血症またはインフルエンザウイルスもしくはRSウイルス感染に基づくサイトカインストームの治療又は予防における使用のための第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第19発明は、動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症または心筋梗塞、糸球体腎炎、血栓症、肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の治療における使用のための第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第20発明は、敗血症の治療又は予防における使用のための第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物に関する。
また、第21発明は、対象においてS1P3レセプターアンタゴニスト作用を誘発するための、第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物の使用に関する。
また、第22発明は、対象においてS1P3レセプターアンタゴニスト作用を誘発する方法であって、有効量の第1〜第7発明のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物をその必要がある対象に投与する方法に関する。
<合成経路A>
具体的には、まず、1,4−ジオキサン、テトラヒドロフラン又はジエチルエーテルなどの反応溶媒中で、−78℃で、一般式(2)で表される化合物を塩基を用いて処理する。その後、生じた一般式(2)で表される化合物のアニオンに一般式(3)で表される化合物を−78℃で作用させ、続いて徐々に常温まで昇温させて一般式(4)で表される化合物を得る。当該反応における塩基は、n−ブチルリチウム又はリチウムジイソプロピルアミドなど、好ましくはn−ブチルリチウムを用いることができる。
なお、本明細書において、常温とは、日本薬局方にて定義されている15〜25℃を意味する。
合成経路Aで一般式(6)
具体的には、まず、1,4−ジオキサン、テトラヒドロフラン又はジエチルエーテルなどの反応溶媒中で、−78℃で、一般式(4)で表される化合物を塩基を用いて処理する。その後、生じた一般式(4)で表される化合物のアニオンに一般式(5)で表される化合物を−78℃で作用させ、続いて徐々に常温まで昇温させて一般式(6)で表される化合物を得る。当該反応における塩基は、n−ブチルリチウム又はリチウムジイソプロピルアミドなど、好ましくはn−ブチルリチウムを用いることができる。
合成経路Aで一般式(7)
具体的には、まず、無機酸又は有機酸中、あるいは無機酸又は有機酸と有機溶媒との混合溶液中、一般式(6)で表される化合物について常温で酸加水分解を行う。このとき、無機酸は、塩酸若しくは臭化水素酸などを用いることができる。また、有機酸は、トリフルオロメタンスルホン酸などを用いることができる。また、有機溶媒は、メタノール、エタノール、テトラヒドロフラン、1,4−ジオキサン又は酢酸エチルなどを用いることができる。このうち、好ましくは塩酸含有1,4−ジオキサン溶液を用いて酸加水分解を行うことが好ましい。
次に、塩基で中和しアミノエステル体を得た後に、溶媒中で、当該アミノエステル体と酸塩化物又は酸無水物とを、0℃〜常温で反応させ、一般式(7)で表される化合物を得る。このとき、溶媒は、酢酸エチル、テトラヒドロフラン、N,N−ジメチルホルムアミド、1,4−ジオキサン、塩化メチレン、クロロホルム、メタノール、エタノール又はアセトニトリルなどを用いることができる。また、酸塩化物は、塩化アセチル若しくは塩化ベンジルオキシカルボニルなどを用いることができる。また、酸無水物は、無水酢酸若しくはジ−t−ブチルジカルボナートなどを用いることができる。このうち、ジ−t−ブチルジカルボナートを用いて反応を行わせることが好ましい。
合成経路Aで一般式(8)
例えば、テトラヒドロフラン、1,4−ジオキサン、エタノール又はメタノールなどの反応溶媒中で、還元剤を用いて一般式(7)で表される化合物を0℃〜加熱還流の温度、好ましくは常温で還元する。還元剤は、ボラン若しくは9-ボラビシクロ[3.3.1]ノナン(9−BBN)のようなアルキルボラン誘導体、又はジイソブチルアルミニウムヒドリド((iBu)2AlH)、水素化ホウ素ナトリウム(NaBH4)、水素化ホウ素リチウム(LiBH4)若しくは水素化アルミニウムリチウム(LiAlH4)などの金属水素錯化合物を用いることができる。好ましくは、還元剤は、水素化ホウ素リチウムである。
合成経路Aで一般式(10)
例えば、当該反応は、トルエン、N,N−ジメチルホルムアミド、1,4−ジオキサン、テトラヒドロフラン又はジエチルエーテルなどの反応溶媒中で、無機塩基又は有機塩基存在下で、触媒を用いて常温〜加熱還流の温度で行うことができる。無機塩基は、炭酸ナトリウム若しくはカリウムt−ブトキシドなどを用いることができる。また、有機塩基は、ジイソプロピエチルアミンなどを用いることができる。また、触媒は、トリス(ジベンジリデンアセトン)ジパラジウム(0)又は酢酸パラジウム(II)などのパラジウム化合物、好ましくはトリス(ジベンジリデンアセトン)ジパラジウム(0)を用いることができる。
また4,5−ビス(ジフェニルホスフィノ)−9,9−ジメチルキサンテン、ビス[2−(ジフェニルホスフィノ)フェニル]エーテル、1,1’−ビス(ジt−ブチルホスフィノ)フェロセンなどのホスフィン化合物を反応促進剤として反応溶媒中に加えることもできる。
合成経路Aで一般式(12)
例えば、当該反応は、四臭化炭素及びピリジンの存在下において、無溶媒もしくは塩化メチレン、クロロホルム、アセトニトリル、酢酸エチル、テトラヒドロフラン又はジエチルエーテルなどを溶媒として用い、0℃〜常温で行うことができる。
合成経路Aで一般式(1d)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は一般式(12)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を酸加水分解又はトリメチルシリルブロミド若しくはトリメチルシリルヨージドなどの求核試薬で処理することによって製造することができる(工程A−7)。
酸加水分解反応の場合、塩酸又は臭化水素酸などの無機酸中、あるいはメタノール又はエタノールなどの有機溶媒と無機酸との混合溶液中、加熱還流の温度で行うことができる。また、求核試薬を用いた処理は、好ましい反応溶媒としてアセトニトリル又は塩化メチレンなどを用い、0℃〜常温でトリメチルシリルブロミド又はトリメチルシリルヨージドを作用させるようにしてもよい。あるいは、求核試薬を用いた処理は、トリメチルシリルクロリドと臭化ナトリウム又はトリメチルシリルクロリドとヨウ化ナトリウムを組み合わせて作用させることでも行うことができる。
合成経路Aで一般式(7)で表される化合物は、例えば以下に示すような合成経路Bにより製造することもできる。
<合成経路B>
合成経路Bで一般式(15)
合成経路Bで一般式(7)で表される化合物は、一般式(15)で表される化合物を用いて工程A−3と同様の方法によって製造することができる(工程B−3)。
合成経路Aで一般式(10)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、例えば以下に示すような合成経路Cにより製造することもできる。
<合成経路C>
合成経路Cで一般式(18)
合成経路Cで一般式(10)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、一般式(18)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を用いて工程A−4と同様の方法によって製造することができる(工程C−3)。
合成経路Cで一般式(18)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、例えば以下に示すような合成経路Dにより製造することもできる。
<合成経路D>
合成経路Dで一般式(20)
合成経路Dで一般式(18)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、一般式(20)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を用いて工程A−3と同様の方法によって製造することができる(工程D−3)。
合成経路Aで一般式(10)で表せる化合物のうち、R1がシアノ基又はアセチル基であり、R5がフェノールの一般的な保護基である化合物、即ち一般式(10a)
<合成経路E>
合成経路Eで一般式(23)
当該反応は、通常のフェノール性水酸基の保護に用いられる手法であれば特に限定されない。例えば、アセトニトリル、テトラヒドロフラン、N,N−ジメチルホルムアミド、塩化メチレン又はクロロホルムなどの溶媒中で、無機塩基又は有機塩基の存在下、一般式(22)で表される化合物に塩化物又は酸塩化物を反応させることで行うことができる。無機塩基は、炭酸カリウムなどを用いることができる。また、有機塩基は、トリエチルアミン若しくはジイソプロピルエチルアミンなどを用いることができる。また、塩化物は、メトキシメチルクロリド、t−ブチルジメチルシリルクロリド若しくはベンジルクロリドなどを用いることができる。また、酸塩化物は、塩化アセチルなどを用いることができる。このうち、メトキシメチルクロリドを用いてフェノール性水酸基の保護を行うことが好ましい。また、当該反応は、0℃〜常温で反応させることで行うことができる。
合成経路Eで一般式(24)
反応は、フェノール性水酸基の保護基の除去に通常に用いられ、かつ、R5aが除去されない手法であれば特に限定されない。例えばR5bがt−ブチルジメチルシリル基などのシリル系保護基の場合を想定する。この場合、当該脱保護反応は、テトラブチルアンモニウムフロリド又はフッ化水素−ピリジンなどのフッ素化合物、好ましくはテトラブチルアンモニウムフロリドを用い、テトラヒドロフラン、アセトニトリル又は塩化メチレンなどの反応溶媒中で行うことができる。また、当該脱保護反応は、0℃〜加熱還流の温度、好ましくは0℃で行うことができる。
合成経路Eで一般式(25)
例えば、当該反応は、塩化メチレン、クロロホルム又はトルエンなどの溶媒を用い、ピリジン又はトリエチルアミンなどの有機塩基存在下、N−フェニルトリフルオロメタンスルホンイミドを0℃〜80℃で、好ましくは常温で作用させることで行うことができる。
例えばR1aがシアノ基の場合を想定する。この場合、当該反応は、シアン化亜鉛存在下、トルエン、N,N−ジメチルホルムアミド、1,4−ジオキサン又はテトラヒドロフランなどの反応溶媒中で、触媒を用い、常温〜加熱還流の温度で行うことができる。触媒は、テトラキストリフェニルホスフィンパラジウム(0)又はトリス(ジベンジリデンアセトン)ジパラジウム(0)などのパラジウム化合物、好ましくはテトラキストリフェニルホスフィンパラジウム(0)を用いることができる。また、反応溶媒中に、1,1’−ビス(ジフェニルホスフィノ)−フェロセン又は1,3−ビス(ジフェニルホスフィノ)−プロパンなどのホスフィン化合物を反応促進剤として加えることもできる。
また、例えばR1aがアセチル基の場合を想定する。この場合、当該反応は、有機塩基存在下、触媒と反応促進剤を用い、トルエン、N,N−ジメチルホルムアミド、1,4−ジオキサン又はテトラヒドロフランなどの溶媒中で、ブチルビニルエーテルを作用させることで行うことができる。有機塩基は、トリエチルアミン又はジイソプロピルエチルアミンなどを用いることができる。また、触媒は、酢酸パラジウム(II)を用いることができる。また、反応促進剤は、1,3−ビス(ジフェニルホスフィノ)−プロパンを用いることができる。また、反応は、常温〜加熱還流の温度で行うことができる。
一般式(1)で表される化合物のうち、Xが-CH2-又は-CHF-、及びYが水素原子である化合物、即ち一般式(1e)
<合成経路F>
合成経路Fで一般式(26)
当該反応は、一般に用いられるアルコールのアルデヒドへの酸化手法を用いることができる。例えば、クロロクロム酸ピリジニウム若しくは二クロム酸ピリジニウムなどの酸化クロム−ピリジン錯体、酸化クロム、炭酸銀若しくは二酸化マンガンなどの金属酸化剤を用いた酸化処理が挙げられる。又は、塩化オキザリル、無水トリフルオロ酢酸、無水酢酸、ジシクロヘキシルカルボジイミド、三酸化硫黄−ピリジン錯体などの各種ジメチルスルホキシド活性化剤を用いたジメチルスルホキシド酸化も挙げられる。
合成経路Fで一般式(29)
当該反応における塩基は、水素化ナトリウム、水素化カリウム、ナトリウムアルコキシド、カリウムアルコキシド又はn−ブチルリチウムなど、好ましくはn−ブチルリチウムを用いることができる。また、反応溶媒は、テトラヒドロフラン、ジエチルエーテル又は1,4−ジオキサンなどを用いることができる。また、反応温度は、−78℃〜常温とすることができる。
合成経路Fで一般式(30)
例えば、当該反応は、接触還元触媒の存在下、エタノール、メタノール、テトラヒドロフラン、N,N−ジメチルホルムアミド又は酢酸エチルなどの溶媒中で、常圧〜加圧の水素圧下において常温で行うことができる。接触還元触媒は、パラジウム炭素、白金炭素、酸化白金、ロジウム炭素又はルテニウム炭素などを用いることができる。
合成経路Fで一般式(1e)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、一般式(30)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を用いて工程A−7と同様の方法によって製造することができる(工程F−4)。
一般式(1)で表される化合物のうち、Xが酸素原子及びYが炭素数1〜6のアルキル基である化合物、即ち一般式(1f)
<合成経路G>
合成経路Gで一般式(31)
で表される化合物とを反応させることによって製造することができる(工程G−1)。
例えば、当該反応は、ジエチルエーテル、1,4−ジオキサン又はテトラヒドロフランなどの溶媒を用い、−78℃〜常温で行うことができる。
合成経路Gで一般式(33)
合成経路Gで一般式(1f)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は一般式(33)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を用いて工程A−7と同様の方法によって製造することができる(工程G−3)。
一般式(1)で表される化合物のうち、Xが-CF2-及びYが水素原子である化合物、即ち一般式(1g)
<合成経路H>
合成経路Hで一般式(35)
具体的には、まず、1,4−ジオキサン、テトラヒドロフラン又はジエチルエーテルなどの反応溶媒中で、−78℃で塩基を用いて一般式(34)で表される化合物を処理する。その後、生じた一般式(34)で表される化合物のアニオンに対し、一般式(26)で表される化合物を−78℃で作用させ、一般式(35)で表される化合物を得る。塩基は、n−ブチルリチウム又はリチウムジイソプロピルアミドなど、好ましくはリチウムジイソプロピルアミドを用いることができる。
合成経路Hで一般式(36)
例えば、当該反応は、塩化メチレン、クロロホルム又はトルエンなどの溶媒中で、有機塩基存在下、スルホン酸塩化物又はスルホン酸無水物を用いて、0℃〜80℃で、好ましくは常温で行うことができる。有機塩基は、ピリジン又はトリエチルアミンなどを用いて行うことができる。また、スルホン酸塩化物は、メタンスルホニルクロライドなどを用いることができる。また、スルホン酸無水物は、メタンスルホン酸無水物などを用いることができる。また、溶媒中に、ヨウ化カリウム又はヨウ化ナトリウム等のハロゲン化アルカリ金属を加えることもできる。
合成経路Hで一般式(37)
例えば、当該反応は、N,N−ジメチルホルムアミド、ジメチルスルフィド又はN−メチルピロリドンなどの反応溶媒中で、アルキルボラン誘導体又は金属水素錯化合物を用いて0℃〜加熱還流の温度で行うことができる。アルキルボラン誘導体は、ボラン若しくは9-ボラビシクロ[3.3.1]ノナン(9−BBN)を用いることができる。また、金属水素錯化合物は、ジイソブチルアルミニウムヒドリド((iBu)2AlH)、水素化ホウ素ナトリウム(NaBH4)、水素化ホウ素リチウム(LiBH4)若しくは水素化アルミニウムリチウム(LiAlH4)などを用いることができる。このうち、水素化ホウ素リチウムを用いて当該反応を行うことが好ましい。
合成経路Hで一般式(1g)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)は、一般式(37)で表される化合物(ただし、R1がカルボキシル基の化合物は除く)を用いて工程A−7と同様の方法によって製造することができる(工程H−4)。
一般式(1d)で表せる化合物のうち、R1がカルボキシル基である化合物、即ち一般式(1h)
<合成経路I>
例えば、当該反応は、水酸化ナトリウム又は水酸化カリウムなどの塩基存在下、水溶液又は含水アルコール溶液中、室温から加熱還流の温度で行うことができる。なお、一般式(1i)で表される化合物は、合成経路Aなどにより製造することができる。
<参考例1>
(2S,5R)−2−(4−ブロモ−2−クロロフェニル)エチル−3,6−ジメトキシ−2−メチル−5−イソプロピル−2,5−ジヒドロピラジン
1H NMR (CDCl3, 400 MHz): δ 0.71 (3H, d, J = 6.7 Hz), 1.09 (3H, d, J = 6.7 Hz), 1.35 (3H, s), 1.78 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.08 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.21-2.31 (1H, m), 2.35 (1H, ddd, J = 13.4, 11.6, 4.9 Hz), 2.46 (1H, ddd, J = 13.4, 11.6, 4.9 Hz), 3.68 (3H, s), 3.69 (3H, s), 4.00 (1H, d, J = 3.7 Hz), 7.02 (1H, d, J = 7.9 Hz), 7.27 (1H, dd, J = 7.9, 1.8 Hz), 7.47 (1H, d, J = 1.8 Hz).
ESIMS (+) : 415 [M+H] +.
<参考例2>
(2R,5R)−2−アリル−2−(4−ブロモ−2−クロロフェニル)エチル−3,6−ジメトキシ−5−イソプロピル−2,5−ジヒドロピラジン
H NMR (CDCl3, 400 MHz): δ 0.69 (3H, d, J = 6.7 Hz), 1.10 (3H, d, J = 6.7 Hz), 1.79 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.02 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.27-2.48 (4H, m), 2.54 (1H, dd, J = 13.4, 7.3 Hz), 3.69 (3H, s), 3.70 (3H, s), 3.95 (1H, d, J = 3.1 Hz), 4.97 (1H, dd, 10.4, 2.4 Hz), 5.01 (1H, d, J = 17.7 Hz), 5.61-5.72 (1H, m), 7.01 (1H, d, J = 7.9 Hz), 7.27 (1H, dd, J = 7.9, 1.8 Hz), 7.47 (1H, d, J = 1.8 Hz).
ESIMS (+) : 441 [M+H] +.
<参考例3>
(S)−4−(4−ブロモ−2−クロロフェニル)−2−t−ブトキシカルボニルアミノ−2−メチル酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 1.45 (9H, s), 1.58 (3H, s), 2.09 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.39 (1H, br s), 2.51 (1H, td, J = 12.8, 4.9 Hz), 2.65 (1H, td, J = 12.8, 4.9 Hz), 3.75 (3H, s), 5.42 (1H, br s), 7.04 (1H, d, J = 7.9 Hz), 7.30 (1H, dd, J = 7.9, 1.8 Hz), 7.48 (1H, d, J = 1.8 Hz).
ESIMS (+) : 420 [M+H] +.
<参考例4>
(R)−2−アリル−4−(4−ブロモ−2−クロロフェニル)−2−t−ブトキシカルボニルアミノ酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 1.45 (9H, s), 2.08 (1H, ddd, J = 13.4, 11.0, 5.5 Hz), 2.39-2.51 (2H, m), 2.51-2.61 (1H, m), 2.67 (1H, td, J = 12.8, 4.9 Hz), 3.00-3.14 (1H, m), 3.74 (3H, s), 5.07 (1H, d, J = 4.9 Hz), 5.10 (1H, s), 5.52-5.69 (1H, m), 7.03 (1H, d, J = 7.9 Hz), 7.29 (1H, dd, J = 7.9, 1.8 Hz), 7.48 (1H, d, J = 1.8 Hz).
ESIMS (+) : 446 [M+H] +.
<参考例5>
(S)−4−(4−ブロモ−2−クロロフェニル)−2−t−ブトキシカルボニルアミノ−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.24 (3H, s), 1.44 (9H, s), 1.81 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.05 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.67 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.74 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 3.63-3.74 (2H, m), 4.07 (1H, br s), 4.67 (1H, s), 7.11 (1H, d, J = 8.6 Hz), 7.31 (1H, dd, J = 8.6, 1.8 Hz), 7.50 (1H, d, J = 1.8 Hz).
ESIMS (+) : 392 [M+H] +.
<参考例6>
(R)−2−[2−(4−ブロモ−2−クロロフェニル)エチル]−2−t−ブトキシカルボニルアミノ−4−ペンテン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.43 (9H, s), 1.80-1.94 (2H, m), 2.32 (1H, td, J = 14.1, 7.9 Hz), 2.44 (1H, dd, J = 14.1, 6.7 Hz), 2.63-2.77 (2H, m), 3.69-3.79 (2H, m), 4.09 (1H, br s), 4.72 (1H, s), 5.19 (1H, dd, J = 6.1, 1.8 Hz), 5.22 (1H, s), 5.80-5.91 (1H, s), 7.11 (1H, d, J = 7.9 Hz), 7.31 (1H, dd, J = 7.9, 1.8 Hz), 7.49 (1H, d, J = 1.8 Hz).
ESIMS (+) : 418 [M+H] +.
<参考例7>
1−(メトキシメトキシ)−4−プロピルベンゼン
1H NMR (CDCl3, 400 MHz): δ 0.93 (3H, t, J = 7.3 Hz), 1.55-1.67 (2H, m), 2.53 (2H, t, J = 7.3 Hz), 3.48 (3H, s), 5.15 (2H, s), 6.95 (2H, dt, J = 8.6, 2.4 Hz), 7.09 (2H, dt, J = 8.6, 2.4 Hz).
EIMS (+) : 180 [M] +.
<参考例8>
1−シクロプロピル−4−(メトキシメトキシ)ベンゼン
1H NMR (CDCl3, 400 MHz): δ 0.59-0.62 (2H, m), 0.86-0.93 (2H, m), 1.80-1.90 (1H, m), 3.47 (3H, s), 5.14 (2H, s), 6.94 (2H, dt, J = 9.2, 2.4 Hz), 7.01 (2H, dt, J = 9.2, 2.4 Hz).
EIMS (+) : 178 [M] +.
<参考例9>
2−(メトキシメトキシ)−5−メチルベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 2.24 (3H, s), 3.50 (3H, s), 3.75 (1H, s), 5.21 (2H, s), 6.88 (1H, dd, J = 8.6, 1.2 Hz), 6.97 (1H, d, J = 8.6 Hz), 7.07 (1H, d, J = 1.2 Hz).
EIMS (+) : 184 [M] +.
<参考例10>
5−エチル−2−(メトキシメトキシ)ベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 1.19 (3H, t, J = 7.9 Hz), 2.54 (2H, q, J = 7.9 Hz), 3.51 (3H, s), 3.76 (1H, s), 5.22 (2H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 7.00 (1H, d, J = 7.9 Hz), 7.09 (1H, d, J = 1.8 Hz).
EIMS (+) : 198 [M] +.
<参考例11>
2−(メトキシメトキシ)−5−プロピルベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 0.92 (3H, t, J = 7.3 Hz), 1.55-1.65 (2H. m), 2.47 (2H, t, J = 7.3 Hz), 3.51 (3H, s), 3.76 (1H, s), 5.21 (2H, s), 6.88 (1H, dd, J = 8.6, 1.8 Hz), 6.99 (1H, d, J = 8.6 Hz), 7.07 (1H, d, J = 1.8 Hz).
EIMS (+) : 212 [M] +.
<参考例12>
2−(メトキシメトキシ)−5−イソプロピルベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 1.21 (6H, t, J = 6.7 Hz), 2.74-2.83 (1H. m), 3.51 (3H, s), 3.78 (1H, s), 5.22 (2H, s), 6.94 (1H, dd, J = 8.6, 2.4 Hz), 7.01 (1H, d, J = 8.6 Hz), 7.12 (1H, d, J = 2.4 Hz).
EIMS (+) : 212 [M] +.
<参考例13>
5−シクロプロピル−2−(メトキシメトキシ)ベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 0.61 (2H, dt, J = 6.1, 4.9 Hz), 0.86-0.92 (2H, m), 1.75-1.86 (1H. m), 3.50 (3H, s), 3.76 (1H, s), 5.20 (2H, s), 6.80 (1H, dd, J = 8.6, 2.4 Hz), 6.98 (1H, d, J = 8.6 Hz), 6.98 (1H, d, J = 2.4 Hz).
EIMS (+) : 210 [M] +.
<参考例14>
6−エトキシ−1,3−ベンゾオキサチオール−2−オン
1H NMR (CDCl3, 400 MHz): δ 1.42 (3H, t, J = 6.7 Hz), 4.02 (2H, q, J = 6.7 Hz), 6.84 (1H, dd, J = 8.6, 2.4 Hz), 6.91 (1H, d, J = 2.4 Hz), 7.18 (1H, d, J = 8.6 Hz).
EIMS (+) : 196 [M] +.
<参考例15>
6−イソプロポキシ−1,3−ベンゾオキサチオール−2−オン
1H NMR (CDCl3, 400 MHz): δ 1.33 (6H, d, J = 6.1 Hz), 4.44-4.53 (1H, m), 6.83 (1H, dd, J = 9.2, 2.4 Hz), 6.91 (1H, d, J = 2.4 Hz), 7.17 (1H, d, J = 9.2 Hz).
EIMS (+) : 210 [M] +.
<参考例16>
5−エトキシ−2−ヒドロキシベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 1.38 (3H, t, J = 7.3 Hz), 3.10 (1H, s), 3.96 (2H, q, J = 7.3 Hz), 5.73 (1H, s), 6.78 (1H, dd, J = 9.2, 3.1 Hz), 6.87 (1H, d, J = 9.2 Hz), 6.98 (1H, d, J = 3.1 Hz).
EIMS (+) : 170 [M] +.
<参考例17>
2−ヒドロキシ−5−イソプロポキシベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 1.29 (6H, d, J = 6.1 Hz), 3.09 (1H, s), 4.33-4.43 (1H, m), 5.74 (1H, s), 6.78 (1H, dd, J = 9.2, 3.1 Hz), 6.86 (1H, d, J = 9.2 Hz), 7.00 (1H, d, J = 3.1 Hz).
EIMS (+) : 184 [M] +.
<参考例18>
(2−メトキシ−5−トリフルオロメチルフェニルチオ)エトキシメタン−1−チオン
1H NMR (CDCl3, 400 MHz): δ 1.31 (3H, t, J = 7.3 Hz), 3.92 (3H, s), 4.60 (2H, q, J = 7.3 Hz), 7.04 (1H, d, J = 8.6 Hz), 7.71 (1H, dd, J = 8.6, 2.4 Hz), 7.73 (1H, d, J = 2.4 Hz).
EIMS (+) : 296 [M] +.
<参考例19>
2−メトキシ−5−トリフルオロメチルベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 3.93 (1H, s), 3.95 (3H, s), 6.90 (1H, d, J = 8.6 Hz), 7.38 (1H, dd, J = 8.6, 2.4 Hz), 7.51 (1H, d, J = 2.4 Hz).
EIMS (+) : 296 [M] +.
<参考例20>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−メチルフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.24 (3H, s), 1.44 (9H, s), 1.80 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.05 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.25 (3H, s), 2.67 (1H, td, J = 12.8, 5.5 Hz), 2.74 (1H, td, J = 12.8, 5.5 Hz), 3.40 (3H, s), 3.62-3.74 (2H, m), 4.09 (1H, br s), 4.68 (1H, s), 5.16 (2H, s), 7.02-7.07 (3H, m), 7.11 (1H, dd, J = 7.9, 1.8 Hz), 7.14 (1H, d, J = 7.9 Hz), 7.26 (1H, d, J = 1.8 Hz).
ESIMS (+) : 496 [M+H] +.
<参考例21>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−エチル−2−メトキシメトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.17 (3H, t, J = 7.3 Hz), 1.24 (3H, s), 1.44 (9H, s), 1.79 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.04 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.55 (2H, q, J = 7.3 Hz), 2.67 (1H, td, J = 12.8, 4.9 Hz), 2.74 (1H, td, J = 12.8, 4.9 Hz), 3.40 (3H, s), 3.62-3.75 (2H, m), 4.09 (1H, br s), 4.68 (1H, s), 5.17 (2H, s), 7.06-7.12 (4H, m), 7.14 (1H, d, J = 7.9 Hz), 7.25 (1H, d, J = 1.8 Hz).
ESIMS (+) : 510 [M+H] +.
<参考例22>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−プロピルフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.90 (3H, t, J = 7.3 Hz), 1.24 (3H, s), 1.44 (9H, s), 1.51-1.61 (2H, m), 1.79 (1H, ddd, J = 13.6, 12.2, 5.5 Hz), 2.04 (1H, ddd, J = 13.6, 12.2, 5.5 Hz), 2.48 (2H, q, J = 7.3 Hz), 2.67 (1H, td, J = 12.8, 4.9 Hz), 2.74 (1H, td, J = 12.8, 4.9 Hz), 3.40 (3H, s), 3.63-3.74 (2H, m), 4.09 (1H, br s), 4.67 (1H, s), 5.16 (2H, s), 7.08 (3H, s), 7.10 (1H, d, J = 1.8 Hz), 7.13 (1H, d, J = 7.9 Hz), 7.24 (1H, d, J = 1.8 Hz).
ESIMS (+) : 524 [M+H] +.
<参考例23>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−イソプロピルフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.19 (6H, t, J = 6.7 Hz), 1.24 (3H, s), 1.44 (9H, s), 1.79 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.03 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.67 (1H, td, J = 12.8, 4.9 Hz), 2.74 (1H, td, J = 12.8, 4.9 Hz), 2.78-2.87 (1H. m), 3.39 (3H, s), 3.63-3.74 (2H, m), 4.08 (1H, br s), 4.67 (1H, s), 5.16 (2H, s), 7.06-7.16 (5H, m), 7.24 (1H, d, J = 1.8 Hz).
ESIMS (+) : 524 [M+H] +.
<参考例24>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シクロプロピル−2−メトキシメトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.58 (2H, dt, J = 6.1, 4.9 Hz), 0.86-0.92 (2H, m), 1.24 (3H, s), 1.44 (9H, s), 1.74-1.85 (2H. m), 1.98-2.08 (1H, m), 2.67 (1H, td, J = 12.8, 4.9 Hz), 2.74 (1H, td, J = 12.8, 4.9 Hz), 3.38 (3H, s), 3.63-3.74 (2H, m), 4.06 (1H, br s), 4.67 (1H, s), 5.15 (2H, s), 6.96 (1H, dd, J = 7.9, 1.8 Hz), 7.00 (1H, d, J = 1.8 Hz), 7.05 (1H, d, J = 7.9 Hz), 7.09 (1H, dd, J = 7.9, 1.8 Hz), 7.13 (1H, d, J = 7.9 Hz), 7.24 (1H, d, J = 1.8 Hz).
ESIMS (+) : 522 [M+H] +.
<参考例25>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−メトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.23 (3H, s), 1.43 (9H, s), 1.78 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.00 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.59-2. 76 (2H, m), 3.61-3.73 (2H, m), 3.77 (3H, s), 4.06 (1H, br s), 4.65 (1H, s), 6.03 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 6.97 (1H, dd, J = 7.9, 3.1 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.02 (1H, d, J = 3.1 Hz), 7.06 (1H, d, J = 1.8 Hz), 7.11 (1H, d, J = 7.9 Hz).
ESIMS (+) : 468 [M+H] +.
<参考例26>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−エトキシ−2−ヒドロキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.22 (3H, s), 1.39 (3H, t, J = 7.3 Hz). 1.43 (9H, s), 1.77 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.00 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.64 (1H, td, J = 12.8, 4.9 Hz), 2.71 (1H, td, J = 12.8, 4.9 Hz), 3.65 (1H, dd, J = 11.6, 4.9 Hz), 3.60 (1H, dd, J = 11.6, 7.3 Hz), 3.97 (2H, q, J = 7.3 Hz), 4.10 (1H, br s), 4.66 (1H, s), 6.03 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 6.96 (1H, dd, J = 8.6, 2.4 Hz), 7.00 (1H, d, J = 8.6 Hz), 7.02 (1H, d, J = 2.4 Hz), 7.06 (1H, d, J = 1.8 Hz), 7.10 (1H, d, J = 7.9 Hz).
ESIMS (+) : 482 [M+H] +.
<参考例27>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロポキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.22 (3H, s), 1.30 (6H, d, J = 6.1 Hz), 1.43 (9H, s), 1.77 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 2.00 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 2.59-2.75 (2H, m), 3.61-3.73 (2H, m), 4.07 (1H, br s), 4.35-4.46 (1H, m), 4.65 (1H, s), 6.04 (1H, s), 6.91 (1H, dd, J = 7.9, 2.4 Hz), 6.95 (1H, dd, J = 8.6, 2.4 Hz), 6.99 (1H, d, J = 8.6 Hz), 7.04 (1H, d, J = 2.4 Hz), 7.06 (1H, d, J = 1.8 Hz), 7.10 (1H, d, J = 7.9 Hz).
ESIMS (+) : 496 [M+H] +.
<参考例28>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.23 (3H, s), 1.43 (9H, s), 1.78 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.01 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.59-2.78 (2H, m), 3.62-3.74 (2H, m), 4.04 (1H, br s), 4.65 (1H, s), 5.01 (2H, s), 6.04 (1H, s), 6.90 (1H, dd, J = 7.9, 1.8 Hz), 7.00 (1H, dd, J = 7.9, 2.4 Hz), 7.04 (1H, dd, J = 7.9, 2.4 Hz), 7.06 (1H, d, J = 2.4 Hz), 7.10 (1H, d, J = 7.9 Hz), 7.11 (1H, d, J = 2.4 Hz), 7.30-7.45 (5H, m).
ESIMS (+) : 544 [M+H] +.
<参考例29>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−クロロ−2−メトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.26 (3H, s), 1.45 (9H, s), 1.83 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 2.08 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 2.71 (1H, td, J = 12.8, 4.9 Hz), 2.78 (1H, td, J = 12.8, 4.9 Hz), 3.68 (1H, dd, J = 11.6, 5.5 Hz), 3.72 (1H, dd, J = 11.6, 7.3 Hz), 3.86 (3H, s), 4.10 (1H, br s), 4.69 (1H, s), 6.04 (1H, s), 6.81 (1H, d, J = 9.2 Hz), 6.97 (1H, d, J = 2.4 Hz), 7.15-7.24 (3H, m), 7.36 (1H, d, J = 1.2 Hz).
ESIMS (+) : 486 [M+H] +.
<参考例30>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−クロロフェニルチオ)−2−クロロフェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.25 (3H, s), 1.44 (9H, s), 1.53 (9H, s), 1.82 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.07 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.70 (1H, td, J = 12.8, 4.9 Hz), 2.77 (1H, td, J = 12.8, 4.9 Hz), 3.67 (1H, dd, J = 11.6, 5.5 Hz), 3.72 (1H, dd, J = 11.6, 7.3 Hz), 4.11 (1H, br s), 4.69 (1H, s), 7.11 (1H, d, J = 8.6 Hz), 7.14 (1H, d, J = 2.4 Hz), 7.21 (2H, d, J = 1.2 Hz), 7.23 (1H, dd, J = 8.6, 2.4 Hz), 7.39 (1H, d, J = 1.2 Hz).
CIMS (+) : 572 [M+H] +.
<参考例31>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.25 (3H, s), 1.44 (9H, s), 1.54 (9H, s), 1.83 (1H, ddd, J = 14,1, 12.2, 5.5 Hz), 2.07 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.65-2.82 (2H, m), 3.67 (1H, dd, J = 11.6, 5.5 Hz), 3.72 (1H, dd, J = 11.6, 7.3 Hz), 4.06 (1H, br s), 4.68 (1H, s), 7.20 (2H, d, J = 1.8 Hz), 7.31 (1H, d, J = 7.9 Hz), 7.40 (1H, d, J = 1.8 Hz), 7.46 (1H, d, J = 1.8 Hz), 7.54 (1H, dd, J = 7.9, 1.8 Hz).
ESIMS (+) : 606 [M+H] +.
<参考例32>
(R)−2−アリル−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.47 (9H, s), 1.92 (1H, dd, J = 6.1, 1.8 Hz), 1.95 (1H, dd, J = 6.1, 1,8 Hz), 2.37 (1H, dd, J = 14.1, 7.9 Hz), 2.48 (1H, dd, J = 14.1, 6.7 Hz), 2.73-2.82 (2H, m), 3.71-3.84 (2H, m), 3.95 (3H, s), 4.12(1H, br s)4.76 (1H, s), 5.22 (1H, d, J = 2.4 Hz), 5.25 (1H, s), 5.86-5.96 (1H, m), 6.98 (1H, d, J = 8.6 Hz), 7.19 (1H, dd, J = 7.9, 1.8 Hz), 7.24 (1H, d, J = 7.9 Hz), 7.35 (1H, d, J = 1.8 Hz), 7.36 (1H, t, J = 1.8 Hz), 7.53 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 546 [M+H] +.
<参考例33>
(R)−2−アリル−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.43 (9H, s), 1.82-1.88 (2H, m), 2.31 (1H, dd, J = 14.1, 8.6 Hz), 2.43 (1H, dd, J = 14.1, 6.7 Hz), 2.69 (2H, dt, J = 11.0, 6.7 Hz), 3.67-3.78 (2H, m), 4.07(1H, br s)4.71 (1H, s), 5.18 (1H, dd, J = 6.1, 1.8 Hz), 5.21 (1H, s), 5.78-5.90 (1H, m), 6.74 (1H, s), 6.91 (1H, dd, J = 7.9, 2.4 Hz), 7.08 (1H, d, J = 2.4 Hz), 7.15 (2H, t, J = 7.9 Hz), 7.63 (1H, dd, J = 7.9, 1.8 Hz), 7.80 (1H, d, J = 2.4 Hz).
ESIMS (+) : 532 [M+H] +.
<参考例34>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル] −2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.30-1.42 (2H, m), 1.44 (9H, s), 1.54 (9H, s), 1.54-1.60 (2H, m), 1.83 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 1.94 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.62-2.77 (2H, m), 3.74(2H, d, J = 6.1 Hz), 4.10(1H, br s)4.62 (1H, s), 7.20 (2H, s), 7.30 (1H, d, J = 8.6 Hz), 7.39 (1H, s), 7.47 (1H, d, J = 1.8 Hz), 7.53 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 634 [M+H] +.
<参考例35>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−メチルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.35 (3H, s), 1.44 (9H, s), 1.76 (1H, ddd, J = 14.1, 12.2, 6.1 Hz), 2.05-2.13 (1H, m), 2.25 (3H, s), 2.62-2.75 (2H, m), 3.40 (3H, s), 3.78 (6H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.22 (1H, dd, J = 9.8, 5.5 Hz), 4.62 (1H, s), 5.16 (2H, s), 7.02-7.07 (3H, m), 7.11 (2H, d, J = 1.8 Hz), 7.25 (1H, d, J = 1.8 Hz).
ESIMS (+) : 604 [M+H] +.
<参考例36>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−エチル−2−メトキシメトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.17 (3H, t, J = 7.3 Hz), 1.35 (3H, s), 1.44 (9H, s), 1.75 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 1.98-2.15 (1H, m), 2.55 (2H, q, J = 7.3 Hz), 2.61-2.76 (2H, m), 3.39 (3H, s), 3.78 (6H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.23 (1H, dd, J = 9.8, 5.5 Hz), 4.62 (1H, s), 5.16 (2H, s), 7.05-7.13 (5H, m), 7.24 (1H, d, J = 1.2 Hz).
ESIMS (+) : 618 [M+H] +.
<参考例37>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−プロピルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 0.90 (3H, t, J = 7.3 Hz), 1.35 (3H, s), 1.44 (9H, s), 1.51-1.61 (2H, m), 1.75 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 1.97-2.13 (1H, m), 2.48 (2H, t, J = 7.3 Hz), 2.61-2.76 (2H, m), 3.39 (3H, s), 3.78 (6H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.23 (1H, dd, J = 9.8, 5.5 Hz), 4.62 (1H, s), 5.16 (2H, s), 7.05-7.13 (5H, m), 7.24 (1H, d, J = 1.2 Hz).
ESIMS (+) : 632 [M+H] +.
<参考例38>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−イソプロピルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.19 (6H, t, J = 7.3 Hz), 1.35 (3H, s), 1.44 (9H, s), 1.75 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.00-2.15 (1H, m), 2.61-2.76 (2H, m), 2.76-2.87 (1H. m), 3.39 (3H, s), 3.78 (6H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.23 (1H, dd, J = 9.8, 5.5 Hz), 4.62 (1H, s), 5.16 (2H, s), 7.05-7.13 (5H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+) : 632 [M+H] +.
<参考例39>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シクロプロピル−2−メトキシメトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 0.58 (2H, dt, J = 6.7, 4.9 Hz), 0.80-0.90 (2H, m), 1.35 (3H, s), 1.44 (9H, s), 1.69-1.85 (2H, m), 1.96-2.14 (1H, m), 2.61-2.76 (2H, m), 3.38 (3H, s), 3.78 (6H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.22 (1H, dd, J = 9.8, 5.5 Hz), 4.62 (1H, s), 5.14 (2H, s), 6.96 (1H, dd, J = 8.6, 1.8 Hz), 7.00 (1H, d, J = 1.8 Hz), 7.03-7.13 (3H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+) : 630 [M+H] +.
<参考例40>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−メトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.34 (3H, s), 1.43 (9H, s), 1.73 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 1.99-2.09 (1H, m), 2.64 (1H, td, J = 13.4, 5.5 Hz), 2.68 (1H, td, J = 13.4, 5.5 Hz), 3.77 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.00 (1H, dd, J = 9.8, 4.9 Hz), 4.20 (1H, dd, J = 9.8, 4.9 Hz), 4.61 (1H, s), 6.05 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 6.97 (1H, dd, J = 8.6, 3.1 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.02 (1H, d, J = 3.1 Hz), 7.06 (1H, d, J = 1.8 Hz), 7.08 (1H, d, J = 8.6 Hz).
ESIMS (+) : 576 [M+H] +.
<参考例41>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−エトキシ−2−ヒドロキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.34 (3H, s), 1.39 (3H, t, J = 7.3 Hz). 1.43 (9H, s), 1.73 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 1.99-2.09 (1H, m), 2.64 (1H, td, J = 13.4, 5.5 Hz), 2.68 (1H, td, J = 13.4, 5.5 Hz), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 3.97 (2H, q, J = 7.3 Hz), 4.00 (1H, dd, J = 9.8, 4.9 Hz), 4.20 (1H, dd, J = 9.8, 4.9 Hz), 4.61 (1H, s), 6.04 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 6.96 (1H, dd, J = 8.6, 2.4 Hz), 7.00 (1H, d, J = 8.6 Hz), 7.02 (1H, d, J = 2.4 Hz), 7.05 (1H, d, J = 1.8 Hz), 7.08 (1H, d, J = 7.9 Hz).
ESIMS (+) : 590 [M+H] +.
<参考例42>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロポキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.30 (6H, d, J = 6.1 Hz), 1.34 (3H, s), 1.43 (9H, s), 1.73 (1H, ddd, J = 13.4, 11.0, 6.1 Hz), 1.98-2.10 (1H, m), 2.59-2.75 (2H, m), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.00 (1H, dd, J = 9.8, 4.9 Hz), 4.20 (1H, dd, J = 9.8, 4.9 Hz), 4.36-4.46 (1H, m), 4.60 (1H, s), 6.04 (1H, s), 6.90 (1H, dd, J = 7.9, 2.4 Hz), 6.95 (1H, dd, J = 9.2, 2.4 Hz), 6.99 (1H, d, J = 9.2 Hz), 7.04 (1H, d, J = 2.4 Hz), 7.06 (1H, d, J = 2.4 Hz), 7.08 (1H, d, J = 7.9 Hz).
ESIMS (+) : 604 [M+H] +.
<参考例43>
(S)−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−t−ブトキシカルボニルアミノ−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.34 (3H, s), 1.43 (9H, s), 1.74 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 1.95-2.14 (1H, m), 2.59-2.73 (2H, m), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.00 (1H, dd, J = 9.8, 4.9 Hz), 4.21 (1H, dd, J = 9.8, 4.9 Hz), 4.61 (1H, s), 5.01 (2H, s), 6.06 (1H, s), 6.89 (1H, dd, J = 7.9, 1.8 Hz), 7.00 (1H, d, J = 9.2 Hz), 7.04 (2H, dd, J = 9.2, 1.8 Hz), 7.08 (1H, d, J = 7.9 Hz), 7.10 (1H, d, J = 2.4 Hz), 7.30-7.43 (5H, m).
ESIMS (+) : 652 [M+H] +.
<参考例44>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−クロロフェニルチオ)−2−クロロフェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.36 (3H, s). 1.45 (9H, s), 1.53 (9H, s), 1.78 (1H, ddd, J = 13.4, 11.6, 5.5 Hz), 2.05-2.17 (1H, m), 2.65-2.79 (2H, m), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.03 (1H, dd, J = 9.8, 4.9 Hz), 4.24 (1H, dd, J = 9.8, 4.9 Hz), 4.64 (1H, s), 7.11 (1H, d, J = 8.6 Hz), 7.14 (1H, d, J = 2.4 Hz), 7.16-7.21 (2H, m), 7.23 (1H, dd, J = 8.6, 2.4 Hz), 7.39 (1H, d, J = 2.4 Hz).
ESIMS (+) : 680 [M+H] +.
<参考例45>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.36 (3H, s). 1.44 (9H, s), 1.54 (9H, s), 1.78 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.06-2.18 (1H, m), 2.65-2.80 (2H, m), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.03 (1H, dd, J = 9.8, 4.9 Hz), 4.23 (1H, dd, J = 9.8, 4.9 Hz), 4.63 (1H, s), 7.19 (2H, d, J = 1.2 Hz), 7.30 (1H, d, J = 8.6 Hz), 7.39 (1H, d, J = 1.2 Hz), 7.46 (1H, d, J = 1.8 Hz), 7.53 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 714 [M+H] +.
<参考例46>
(R)−2−アリル−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシブタン
1H NMR (CDCl3, 400 MHz): δ 1.43 (9H, s), 1.75-1.78 (1H, m), 1.90-2.03 (1H, m), 2.41-2.55 (2H, m), 2.64-2.75 (2H, m), 3.78 (6H, d, J = 11.0 Hz), 4.08 (1H, dd, J = 9.8, 4.9 Hz), 4.19 (1H, dd, J = 9.8, 4.9 Hz), 4.58 (1H, s), 5.18 (1H, s), 5.21 (1H, d, J = 6.1 Hz), 5.73-5.87 (1H, m), 6.80 (1H, s), 6.90 (1H, dd, J = 7.9, 1.8 Hz), 7.09 (1H, d, J = 1.8 Hz), 7.12 (1H, d, J = 7.9 Hz), 7.15(1H, d, J = 8.6 Hz), 7.63 (1H, dd, J = 8.6, 1.8 Hz), 7.80 (1H, d, J = 1.8 Hz).
ESIMS (+) : 640 [M+H] +.
<参考例47>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.31-1.42 (3H, m). 1.44 (9H, s), 1.54 (9H, s), 1.59-1.72 (1H, m), 1.75-1.85 (1H, m), 1.95-2.11 (1H, m), 2.66-2.74 (2H, m), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.11 (1H, dd, J = 9.8, 4.9 Hz), 4.25 (1H, dd, J = 9.8, 4.9 Hz), 4.51 (1H, s), 7.19 (2H, d, J = 1.8 Hz), 7.30 (1H, d, J = 7.9 Hz), 7.39 (1H, s), 7.46 (1H, d, J = 1.8 Hz), 7.53 (1H, dd, J = 7.9, 1.8 Hz).
ESIMS (+) : 742 [M+H] +.
旋光度:[α]D 24 -8.32 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.27 (3H, s), 1.69-1.85 (2H, m), 2.17 (3H, s), 2.66 (2H, t, J = 8.6 Hz), 3.85 (1H, dd, J = 11.0, 4.9 Hz), 3.92 (1H, dd, J = 11.0, 4.9 Hz), 6.86 (1H, d, J = 8.6 Hz), 7.01-7.10 (4H, m), 7.25 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 432.07951 (C18H24ClNO5PSとして計算値 432.08013).
元素分析 : 実測値 C 47.06%, H 5.35%, N 2.95%, C18H23ClNO5PS. 1.5 H2Oとして計算値 C 47.11%, H 5.71%, N 3.05%.
旋光度:[α]D 25 -9.94 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.09 (3H, t, J = 7.3 Hz), 1.27 (3H, s), 1.67-1.86 (2H, m), 2.47 (2H, q, J = 7.3 Hz), 2.66 (2H, t, J = 8.6 Hz), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 6.88 (1H, d, J = 7.9 Hz), 7.04 (2H, dd, J = 7.9, 1.8 Hz), 7.07-7.14 (2H, m), 7.25 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 446.09569 (C19H26ClNO5PSとして計算値 446.09578).
元素分析 : 実測値 C 48.89%, H 5.66%, N 2.75%, C19H25ClNO5PS. H2Oとして計算値 C 49.19%, H 5.87%, N 3.02%.
旋光度:[α]D 25 -9.86 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 0.82 (3H, t, J = 7.3 Hz), 1.27 (3H, s), 1.43-1.56 (2H, m), 1.68-1.85 (2H, m), 2.42 (2H, t, J = 7.3 Hz), 2.65 (1H, d, J = 7.9 Hz), 2.67 (1H, d, J = 7.9 Hz), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.92 (1H, dd, J = 11.0, 4.9 Hz), 6.88 (1H, d, J = 7.9 Hz), 7.00-7.11 (4H, m), 7.24 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 460.11106 (C20H28ClNO5PSとして計算値 460.11143).
旋光度:[α]D 25 -8.12 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.12 (6H, d, J = 6.7 Hz), 1.27 (3H, s), 1.67-1.87 (2H, m), 2.66 (2H, t, J = 8.6 Hz), 2.74-2.81 (1H, m), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 6.89 (1H, d, J = 7.9 Hz), 7.03 (1H, dd, J = 7.9, 1.8 Hz), 7.05 (1H, s), 7.11-7.17(2H, m), 7.25 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 460.11124 (C20H28ClNO5PSとして計算値 460.11143).
元素分析 : 実測値 C 50.13%, H 5.88%, N 2.72%, C20H27ClNO5PS. H2Oとして計算値 C 50.26%, H 6.12%, N 2.93%.
旋光度:[α]D 25 -8.15 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 0.52 (2H, dt, J = 6.1, 4.3 Hz), 0.80-0.86 (2H, m), 1.28 (3H, s), 1.67-1.86 (3H, m), 2.66 (2H, t, J = 8.6 Hz), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 6.85 (1H, d, J = 8.6 Hz), 6.96 (1H, dd, J = 8.6, 2.4 Hz), 7.01 (1H, d, J = 2.4 Hz), 7.04 (1H, dd, J = 7.9, 1.8 Hz), 7.05 (1H, s), 7.11-7.17(2H, m), 7.25 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 458.09631 (C20H26ClNO5PSとして計算値 458.09578).
旋光度:[α]D 25 -8.31 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.23 (3H, s), 1.64-1.84 (2H, m), 2.66 (2H, t, J = 7.9 Hz), 3.63 (3H, s), 3.76 (2H, d, J = 11.0 Hz), 6.73 (1H, d, J = 3.1 Hz), 6.83 (1H, dd, J = 8.6, 3.1 Hz), 6.87 (1H, d, J = 8.6 Hz), 7.08 (1H, dd, J = 7.9, 1.8 Hz), 7.12 (1H, d, J = 1.8 Hz), 7.28 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 448.07498 (C18H24ClNO6PSとして計算値 448.07505).
元素分析 : 実測値 C 45.69%, H 5.08%, N 2.96%, C18H23ClNO6PS. 1.2 H2Oとして計算値 C 46.06%, H 5.45%, N 2.98%.
旋光度:[α]D 25 -8.50 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.23 (3H, t, J = 6.7 Hz), 1.28 (3H, s), 1.70-1.88 (2H, m), 2.68 (2H, t, J = 7.9 Hz), 3.87 (2H, q, J = 6.7 Hz), 3.88 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 6.71 (1H, d, J = 2.4 Hz), 6.83 (1H, dd, J = 9.2, 2.4 Hz), 6.86 (1H, d, J = 9.2 Hz), 7.11 (1H, dd, J = 7.9, 1.8 Hz), 7.13 (1H, d, J = 1.8 Hz), 7.28 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 462.09023 (C19H26ClNO6PSとして計算値 462.09070).
元素分析 : 実測値 C 47.55%, H 5.32%, N 2.55%, C19H25ClNO6PS. H2Oとして計算値 C 47.55%, H 5.67%, N 2.92%.
旋光度:[α]D 25 -8.51 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.16 (6H, d, J = 6.1 Hz), 1.28 (3H, s), 1.71-1.86 (2H, m), 2.68 (2H, t, J = 8.6 Hz), 3.88 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 4.31-4.40 (1H, m), 6.69 (1H, d, J = 3.1 Hz), 6.81 (1H, dd, J = 8.6, 3.1 Hz), 6.85 (1H, d, J = 8.6 Hz), 7.12 (1H, dd, J = 7.9, 1.8 Hz), 7.14 (1H, d, J = 1.8 Hz), 7.28 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 476.10592 (C20H28ClNO6PSとして計算値 476.10635).
元素分析 : 実測値 C 49.21%, H 5.61%, N 2.72%, C20H27ClNO6PS. 0.7H2Oとして計算値 C 49.17%, H 5.86%, N 2.87%.
旋光度:[α]D 25 -9.77 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.27 (3H, s), 1.68-1.86 (2H, m), 2.67 (2H, t, J = 8.6 Hz), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.92 (1H, dd, J = 11.0, 4.9 Hz), 4.95 (2H, s), 6.78 (1H, d, J = 3.1 Hz), 6.85 (1H, dd, J = 9.2, 3.1 Hz), 6.85 (1H, d, J = 9.2 Hz), 7.08 (1H, dd, J = 7.9, 1.8 Hz), 7.12 (1H, d, J = 1.8 Hz), 7.28-7.31 (6H, m).
HRESIMS (+) : 524.10694 (C24H28ClNO6PSとして計算値 524.10635).
元素分析 : 実測値 C 52.62%, H 5.05%, N 2.50%, C24H27ClNO6PS. 1.2H2Oとして計算値 C 52.83%, H 5.43%, N 2.57%.
旋光度:[α]D 25 -8.28 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.29 (3H, s), 1.70-1.90 (2H, m), 2.70 (2H, t, J = 8.6 Hz), 3.87 (1H, dd, J = 11.0, 4.9 Hz), 3.94 (1H, dd, J = 11.0, 4.9 Hz), 6.94 (1H, d, J = 8.6 Hz), 7.08 (1H, d, J = 2.4 Hz), 7.19 (1H, dt, J = 7.9, 1.8 Hz), 7.23 (1H, dt, J = 8.6, 2.4 Hz), 7.26 (1H, t, J = 8.6 Hz), 7.33 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 452.02541 (C17H21Cl2NO5PSとして計算値 452.02551).
元素分析 : 実測値 C 43.98%, H 4.46%, N 3.15%, C17H20Cl2NO5PS. 0.5 H2Oとして計算値 C 44.26%, H 4.59%, N 3.04%.
旋光度:[α]D 24 -7.12 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.28 (3H, s), 1.71-1.88 (2H, m), 2.70 (2H, t, J = 8.6 Hz), 3.87 (1H, dd, J = 11.0, 4.9 Hz), 3.94 (1H, dd, J = 11.0, 4.9 Hz), 7.09 (1H, d, J = 8.6 Hz), 7.18 (1H, dd, J = 8.6, 1.8 Hz), 7.27 (1H, d, J = 1.8 Hz), 7.33 (1H, d, J = 8.6 Hz), 7.39 (1H, d, J = 1.8 Hz), 7.55 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 486.05108 (C18H21ClF3NO5PSとして計算値 486.05187).
元素分析 : 実測値 C 42.61%, H 4.00%, N 2.76%, C18H20ClF3NO5PS. H2Oとして計算値 C 42.91%, H 4.40%, N 2.78%.
旋光度:[α]D 25 -7.41 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.65-1.73 (2H, m), 2.39 (2H, d, J = 7.3 Hz), 2,66-2.74 (2H, m), 3.42-3.53 (2H, m), 5.19 (1H, dd, J = 10.4, 1.8 Hz), 5.24 (1H, dd, J = 17.1, 1.8 Hz), 5.55 (1H, s), 5.75-5.88 (1H, m), 7.10 (1H, d, J = 8.6 Hz), 7.18 (1H, dd, J = 8.6, 1.8 Hz), 7.25 (1H, d, J = 1.8 Hz), 7.31 (1H, d, J = 8.6 Hz), 7.36 (1H, d, J = 1.8 Hz), 7.55 (1H, d, J = 8.6 Hz), 7.94 (3H, br s).
HRESIMS (+) : 512.06693 (C20H23ClF3NO5PSとして計算値 512.06752).
元素分析 : 実測値 C 45.80%, H 4.08%, N 2.61%, C20H22ClF3NO5PS. 0.5H2Oとして計算値 C 46.12%, H 4.45%, N 2.69%.
旋光度:[α]D 25 -7.67 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 0.90 (3H, t, J = 7.3 Hz), 1.26-1.40 (2H, m), 1.54-1.66 (2H, m), 1.70-1.82 (2H, m), 2,61-2.75 (2H, m), 3.86-3.97 (2H, m), 7.10 (1H, d, J = 7.9 Hz), 7.19 (1H, dd, J = 7.9, 1.8 Hz), 7.27 (1H, d, J = 1.8 Hz), 7.34 (1H, d, J = 7.9 Hz), 7.40 (1H, d, J = 1.8 Hz), 7.56 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 514.08255 (C20H25ClF3NO5PSとして計算値 514.08317).
<参考例48>
2−クロロ−4−(2−メトキシフェニルチオ)ベンズアルデヒド
1H NMR (CDCl3, 400 MHz): δ 3.83 (3H, s), 6.98-7.08 (4H, m), 7.49 (1H, td, J = 7.9, 1.2 Hz), 7.52 (1H, dd, J = 7.9, 1.2 Hz), 7.74 (1H, d, J = 7.9 Hz), 10.34 (1H, s).
EIMS (+) : 278 [M] +.
<参考例49>
[2−クロロ−4−(2−メトキシフェニルチオ)フェニル]アセトアルデヒド
1H NMR (CDCl3, 400 MHz): δ 3.80 (2H, d, J = 1.8 Hz), 3.86 (3H, s), 6.92-6.99 (2H, m), 7.12 (2H, d, J = 1.8 Hz), 7.29 (2H, dd, J = 7.9, 1.8 Hz), 7.35 (1H, td, J = 7.9, 1.8 Hz), 9.73 (1H, t, J = 1.8 Hz).
EIMS (+) : 292 [M] +.
<参考例50>
2−クロロ−1−(2−ヨードエチル)−4−(2−メトキシフェニルチオ)ベンゼン
1H NMR (CDCl3, 400 MHz): δ 3.25 (2H, ddd, J = 8.6, 6.7, 1.8 Hz), 3.34 (2H, ddd, J = 8.6, 6.7, 1.8 Hz), 3.86 (3H, s), 6.90-6.96 (2H, m), 7.10 (1H, dd, J = 7.9, 1.8 Hz), 7.14 (1H, d, J = 7.9 Hz), 7.21-7.26 (2H, m), 7.32 (1H, td, J = 7.9, 1.8 Hz).
EIMS (+) : 404 [M] +.
<参考例51>
(2S,5R)−2−[2−クロロ−4−(2−メトキシフェニルチオ)フェニル]エチル−3,6−ジメトキシ−2−メチル−5−イソプロピル−2,5−ジヒドロピラジン
1H NMR (CDCl3, 400 MHz): δ 0.71 (3H, d, J = 6.7 Hz), 1.09 (3H, d, J = 6.7 Hz), 1.36 (3H, s), 1.80 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.11 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.21-2.33 (1H, m), 2.38 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.46 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 3.68 (3H, s), 3.69 (3H, s), 3.87 (3H, s), 3.99 (1H, d, J = 3.7 Hz), 6.85-6.93 (2H, m), 7.07 (1H, d, J = 7.9 Hz), 7.11 (1H, dd, J = 7.9, 1.8 Hz), 7.12 (1H, dd, J = 7.9, 1.8 Hz) , 7.21-7.26 (2H, m).
ESIMS (+) : 475 [M+H] +.
<参考例52>
(S)−4−[2−クロロ−4−(2−メトキシフェニルチオ)フェニル]−2−t−ブトキシカルボニルアミノ−2−メチル酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 1.45 (9H, s), 1.58 (3H, s), 2.11 (1H, ddd, J = 13.4, 11.6, 4.9 Hz), 2.38 (1H, br s), 2.52 (1H, td, J = 12.8, 4.9 Hz), 2.67 (1H, td, J = 12.8, 4.9 Hz), 3.74 (3H, s), 3.86 (3H, s), 5.41 (1H, br s), 6.91 (2H, td, J = 7.9, 1.8 Hz), 7.08 (1H, d, J = 7.9 Hz), 7.10 (1H, d, J = 1.8 Hz), 7.14 (1H, td, J = 7.9, 1.8Hz), 7.28 (2H, td, J = 7.9, 1.8 Hz).
ESIMS (+) : 480 [M+H] +.
<参考例53>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.25 (3H, s), 1.44 (9H, s), 1.81 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.06 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.68 (1H, td, J = 12.8, 4.9 Hz), 2.75 (1H, td, J = 12.8, 4.9 Hz), 3.63-3.75 (2H, m), 3.87 (3H, s), 4.09 (1H, br s), 4.68 (1H, s), 6.91 (2H, td, J = 7.3, 1.2 Hz), 7.09-7.18 (3H, m), 7.28 (1H, dd, J = 7.3, 1.2 Hz),.
ESIMS (+) : 452 [M+H] +.
<参考例54>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシフェニルチオ)−2−クロロフェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.35 (3H, s), 1.44 (9H, s), 1.52 (9H, s), 1.76 (1H, ddd, J = 13.4, 11.0, 5.5 Hz), 2.02-2.16 (1H, m), 2.61-2.77 (2H, m), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 5.5 Hz), 4.22 (1H, dd, J = 9.8, 5.5 Hz), 4.63 (1H, s), 7.09-7.17 (2H, m), 7.19 (2H, d, J = 7.9 Hz), 7.27-7.35 (3H, m).
ESIMS (+) : 646 [M+H] +.
旋光度:[α]D 27 −9.06 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.26 (3H, s), 1.66-1.85 (2H, m), 2.65 (2H, t, J = 8.6 Hz), 3.84 (1H, dd, J = 11.0, 5.5 Hz), 3.91 (1H, dd, J = 11.0, 5.5 Hz), 6.81 (1H, t, J = 7.3 Hz), 6.94 (1H, d, J = 7.3 Hz), 7.06 (1H, d, J = 7.3 Hz, 7.07 (1H, s), 7.21 (2H, d, J = 7.9 Hz), 7.25 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 418.06445 (C17H22ClNO5PSとして計算値
418.06448).
元素分析 : 実測値 C 47.91%, H 4.94%, N 3.21%, C17H21ClNO5PS. 0.4H2Oとして計算値 C 48.04%, H 5.17%, N 3.30%.
<参考例55>
6−t−ブチルジメチルシリルオキシ−1,3−ベンゾオキサチオール−2−オン
1H NMR (CDCl3, 400 MHz): δ 0.20 (6H, s), 0.98 (9H, s), 6.77 (1H, dd, J = 8.6, 2.4 Hz), 6.87 (1H, d, J = 2.4 Hz), 7.14 (1H, d, J = 8.6 Hz).
CIMS (+) : 283 [M+H] +.
<参考例56>
5−t−ブチルジメチルシリルオキシ−2−ヒドロキシベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 0.16 (6H, s), 0.97 (9H, s), 3.06 (1H, s), 5.73 (1H, s), 6.71 (1H, dd, J = 8.6, 2.4 Hz), 6.81 (1H, d, J = 2.4 Hz), 6.93 (1H, d, J = 8.6 Hz).
CIMS (+) : 257 [M+H] +.
<参考例57>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(5−t−ブチルジメチルシリルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.17 (6H, s), 0.97 (9H, s), 1.23 (3H, s), 1.43 (9H, s), 1.77 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.00 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.58-2.76 (2H, m), 3.65 (1H, dd, J = 11.6, 4.9 Hz), 3.70 (1H, dd, J = 11,6, 7.3 Hz), 4.07 (1H, br s), 4.65 (1H, s), 6.05 (1H, s), 6.90 (2H, td, J = 8.6, 2.4 Hz), 6.94 (1H, d, J = 8.6 Hz), 6.98 (1H, d, J = 2.4 Hz), 7.03 (1H, d, J = 2.4 Hz), 7.10 (1H, d, J = 8.6 Hz).
ESIMS (+) : 568 [M+H] +.
<参考例58>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(5−t−ブチルジメチルシリルオキシ−2−メトキシメトキシフェニルチオ)−2−クロロフェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.08 (6H, s), 0.91 (9H, s), 1.25 (3H, s), 1.44 (9H, s), 1.80 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.02 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.69 (1H, td, J = 12.8, 4.9 Hz), 2.76 (1H, td, J = 12.8, 4.9 Hz), 3.45 (3H, s), 3.67 (1H, dd, J = 11.6, 4.9 Hz), 3.72 (1H, dd, J = 11,6, 7.3 Hz), 4.08 (1H, br s), 4.68 (1H, s), 5.13 (2H, s), 6.53 (1H, d, J = 3.1 Hz), 6.68 (1H, dd, J = 9.2, 3.1 Hz), 7.00 (1H, d, J = 9.2 Hz), 7.18 (2H, d, J = 1.8 Hz), 7.32 (1H, d, J = 1.8 Hz).
ESIMS (+) : 612 [M+H] +.
<参考例59>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−ヒドロキシ−2−メトキシメトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
mol / L, 1.0 mL)を加えて反応液とした。当該反応液を、氷冷しながら30分間攪拌した。反応液に水を加え、酢酸エチルで抽出し、水、飽和食塩水の順に洗浄後、無水硫酸ナトリウムを用いて乾燥した。無水硫酸ナトリウムを濾過により除去した後、溶媒を減圧留去しシリカゲルカラムクロマトグラフィー(ヘキサン : 酢酸エチル = 1 : 1)を用いて精製し、目的物(486 mg)を無色油状物として得た。
1H NMR (DMSO-d6, 400 MHz): δ1.17 (3H, s), 1.37 (9H, s), 1.65-1.77 (1H, m), 1.81-1.95 (1H, m), 2.60 (2H, t, J = 8.6 Hz), 3.29 (3H, s), 3.36-3.41 (2H, m), 4.72 (1H, t, J = 5.5 Hz), 5.08 (2H, s), 6.28 (1H, s), 6.42 (1H, d, J = 3.1 Hz), 6.63 (1H, dd, J = 9.2, 3.1 Hz), 6.98 (1H, d, J = 9.2 Hz), 7.22 (1H, dd, J = 7.9, 1.8 Hz), 7.28 (1H, d, J = 1.8 Hz), 7.30 (1H, d, J = 7.9 Hz), 9.24 (1H, s).
ESIMS (+) : 498 [M+H] +.
<参考例60>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメタンスルホニルオキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.26 (3H, s), 1.45 (9H, s), 1.84 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.06 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.74 (1H, td, J = 12.8, 4.9 Hz), 2.81 (1H, td, J = 12.8, 4.9 Hz), 3.47 (3H, s), 3.68 (1H, dd, J = 11.6, 4.9 Hz), 3.73 (1H, dd, J = 11,6, 7.3 Hz), 4.08 (1H, br s), 4.69 (1H, s), 5.24 (2H, s), 6.78 (1H, d, J = 3.1 Hz), 7.05 (1H, dd, J = 9.2, 3.1 Hz), 7.16 (1H, d, J = 9.2 Hz), 7.27 (2H, d, J = 1.8 Hz), 7.43 (1H, d, J = 1.8 Hz).
ESIMS (+) : 630 [M+H] +.
<参考例61>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シアノ−2−メトキシメトキシフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.26 (3H, s), 1.45 (9H, s), 1.84 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.07 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.69-2.85 (2H, m), 3.47 (3H, s), 3.66-3.75 (2H, m), 4.06 (1H, br s), 4.69 (1H, s), 5.24 (2H, s), 6.78 (1H, d, J = 3.1 Hz), 7.05 (1H, dd, J = 9.2, 3.1 Hz), 7.16 (1H, d, J = 9.2 Hz), 7.27 (2H, s), 7.43 (1H, d, J = 1.2 Hz).
ESIMS (+) : 490 [M+H] +.
<参考例62>
(S)−4−[4−(5−アセチル−2−メトキシメトキシフェニルチオ)−2−クロロフェニル] −2−t−ブトキシカルボニルアミノ−2−メチルブタン−1−オール
μL)及び参考例60の化合物(200 mg)のN,N−ジメチルホルムアミド(3.5 mL)溶液を加え、80℃で18時間攪拌した。反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出し、水、飽和食塩水の順に洗浄後、無水硫酸ナトリウムを用いて乾燥した。無水硫酸ナトリウムを濾過により除去した後、溶媒を減圧留去し、シリカゲルカラムクロマトグラフィー(ヘキサン : 酢酸エチル = 2 : 1)を用いて精製し、目的物(117 mg)を無色油状物として得た。
1H NMR (CDCl3, 400 MHz): δ 1.25 (3H, s), 1.44 (9H, s), 1.81 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.04 (1H, ddd, J = 14.1, 12.2, 5.5 Hz), 2.50 (3H, s), 2.64-2.81 (2H, m), 3.38 (3H, s), 3.63-3.74 (2H, m), 4.07 (1H, br s), 4.68 (1H, s), 5.27 (2H, s), 7.13-7.21 (3H, m), 7.31 (1H, d, J = 1.8 Hz), 7.82 (1H, d, J = 1.8 Hz), 7.87 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 524 [M+H] +.
<参考例63>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シアノ−2−メトキシメトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.38 (3H, s), 1.45 (9H, s), 1.82 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.07-2.21 (1H, m), 2.69-2.84 (2H, m), 3.45 (3H, s), 3.79 (3H, d, J = 11.0 Hz), 3.80 (3H, d, J = 11.0 Hz), 4.04 (1H, dd, J = 9.8, 5.5 Hz), 4.25 (1H, dd, J = 9.8, 5.5 Hz), 4.65 (1H, s), 5.29 (2H, s), 7.15 (1H, d, J = 1.8 Hz), 7.17 (1H, d, J = 8.6 Hz), 7.25-7.27 (2H, m), 7.42 (1H, t, J = 1.8 Hz), 7.46 (1H, J = 8.6, 1.8 Hz).
ESIMS (+) : 615 [M+H] +.
<参考例64>
(S)−4−[4−(5−アセチル−2−メトキシメトキシフェニルチオ)−2−クロロフェニル]−2−t−ブトキシカルボニルアミノ−1−ジメトキシホスホリルオキシ−2−メチルブタン
1H NMR (CDCl3, 400 MHz): δ 1.36 (3H, s), 1.44 (9H, s), 1.76 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 1.98-2.17 (1H, m), 2.50 (3H, s), 2.64-2.76 (2H, m), 3.38 (3H, s), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.02 (1H, dd, J = 9.8, 4.9 Hz), 4.23 (1H, dd, J = 9.8, 4.9 Hz), 4.63 (1H, s), 5.26 (2H, s), 7.16 (2H, S), 7.20 (1H, t, J = 7.9 Hz), 7.29 (1H, s), 7.84 (1H, d, J = 1.8 Hz), 7.88 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 632 [M+H] +.
旋光度:[α]D 25 -6.74 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.27 (3H, s), 1.69-1.87 (2H, m), 2.70 (2H, t, J = 8.6 Hz), 3.86 (1H, dd, J = 11.0, 4.9 Hz), 3.93 (1H, dd, J = 11.0, 4.9 Hz), 7.04 (1H, d, J = 7.9 Hz), 7.20 (1H, dd, J = 7.9, 1.2 Hz), 7.26-7.44 (2H, m), 7.48 (1H, d, J = 1.8 Hz), 7.63 (1H, dd, J = 7.9, 1.8 Hz).
HRESIMS (+) : 443.05981 (C18H21ClN2O5PSとして計算値 443.05973)
旋光度:[α]D 25 -9.53 (c 0.50, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.27 (3H, s), 1.68-1.86 (2H, m), 2.43 (3H, s), 2.68 (2H, t, J = 8.6 Hz), 3.85 (1H, dd, J = 11.0, 4.9 Hz), 3.92 (1H, dd, J = 11.0, 4.9 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.13 (1H, dd, J = 7.9, 1.2 Hz), 7.19 (1H, d, J = 1.8 Hz), 7.29 (1H, d, J = 7.9 Hz), 7.77 (1H, d, J = 1.8 Hz), 7.85 (1H, dd, J = 7.9, 1.8 Hz).
HRESIMS (+) : 460.07487 (C19H24ClNO6PSとして計算値 460.07505)
元素分析 : 実測値 C 47.44%, H 5.07%, N 2.59%, C19H23ClNO6PS. H2Oとして計算値 C 47.75%, H 5.27%, N 2.93%.
<参考例65>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.22 (3H, s), 1.43 (9H, s), 1.79 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.01 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.60-2.76 (2H, m), 3.61-3.73 (2H, m), 4.00 (1H, br s), 4.65 (1H, s), 6.74 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 7.09 (1H, d, J = 1.8 Hz), 7.12-7.18 (2H, m), 7.63 (1H, dd, J = 8.6, 2.4 Hz), 7.80 (1H, d, J = 2.4 Hz).
ESIMS (+) : 506 [M+H] +.
<参考例66>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 1.25 (3H, s), 1.44 (9H, s), 1.82 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.06 (1H, ddd, J = 13.4, 12.2, 5.5 Hz), 2.66-2.83 (2H, m), 3.41 (3H, s), 3.65-3.74 (2H, m), 4.03 (1H, br s), 4.67 (1H, s), 5.25 (2H, s), 7.16-7.24 (3H, m), 7.35 (1H, d, J = 1.8 Hz), 7.36 (1H, d, J = 1.8 Hz), 7.47 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 550 [M+H] +.
<参考例67>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブタン−1−アール
1H NMR (CDCl3, 400 MHz): δ 1.41 (3H, s), 1.46 (9H, s), 1.91-2.08 (1H, m), 2.16-2.31 (1H, m), 2.57 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.68 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 3.41 (3H, s), 5.24 (1H, br s), 5.25 (2H, s), 7.14 (1H, d, J = 7.9 Hz), 7.17 (1H, dd, J = 7.9, 1.8 Hz), 7.21 (1H, d, J = 7.9 Hz), 7.33 (1H, d, J = 1.8 Hz), 7.38 (1H, d, J = 1.8 Hz), 7.48 (1H, dd, J = 7.9, 1.8 Hz), 9.40 (1H, s).
ESIMS (-) : 546 [M-H] +.
<参考例68>
(S)−3−t−ブトキシカルボニルアミノ−5−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−3−メチル−1−ペンテニルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz): δ 1.44 (3H, s), 1.46 (9H, s), 1.90 (1H, td, J = 12.2, 4.9 Hz), 2.06-2.17 (1H, m), 2.61-2.78 (2H, m), 3.41 (3H, s), 3.73 (6H, d, J = 11.0 Hz), 4.65 (1H, br s), 5.25 (2H, s), 5.70 (1H, t, J = 17.7 Hz), 6.82 (1H, dd, J = 22.6, 17.7 Hz), 7.16-7.18 (2H, m), 7.21 (1H, d, J = 8.6 Hz), 7.34 (1H, d, J = 1.8 Hz), 7.34 (1H, d, J = 1.8 Hz), 7.48 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 654 [M+H] +.
<参考例69>
(S)−3−t−ブトキシカルボニルアミノ−5−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−3−メチルペンチルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz): δ 1.30 (3H, s), 1.46 (9H, s), 1.77-1.86 (4H, m), 2.04-2.15 (1H, m), 2.16-2.28 (1H, m), 2.66-2.82 (2H, m), 3.45 (3H, s), 3.79 (6H, d, J = 11.0 Hz), 4.44 (1H, br s), 5.30 (2H, s), 7.17-7.28 (3H, m), 7.38-7.42 (2H, m), 7.52 (1H, dd, J = 7.9, 2.4 Hz).
ESIMS (+) : 656 [M+H] +.
旋光度:[α]D 25 -14.62 (c 0.11, MeOH).
1H NMR (DMSO-d6-dTFA, 400 MHz) :δ 1.23 (3H, s), 1.37-1.52 (2H, m), 1.64-1.86 (4H, m), 2.56-2.70 (2H, m), 7.08 (2H, d, J = 8.6 Hz), 7.21 (1H, s), 7.24-7.33 (1H, m), 7.41 (1H, s), 7.51 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 484.07277 (C19H23ClF3NO4PSとして計算値 484.07260)
<参考例70>
(2S,5R)−2−(4−ブロモ−2−クロロフェニル)エチル−3,6−ジメトキシ−2−プロピル−5−イソプロピル−2,5−ジヒドロピラジン
H NMR (CDCl3, 400 MHz): δ 0.70 (3H, d, J = 6.7 Hz), 0.86 (3H, t, J = 7.3 Hz), 1.11 (3H, d, J = 6.7 Hz), 1.15-1.30 (2H, m), 1.49-1.62 (1H, m), 1.71-1.84 (2H, m), 1.98 (1H, td, J = 12.4, 4.8 Hz), 2.29-2.47 (3H, m), 3.69 (3H, s), 3.70 (3H, s), 3.95 (1H, d, J = 3.0 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.27 (1H, dd, J = 7.9, 1.8 Hz), 7.46 (1H, d, J = 1.8 Hz).
ESIMS (+) :443 [M+H] +.
<参考例71>
(2S,5R)−2−(4−ブロモ−2−クロロフェニル)エチル−2−ブチル−3,6−ジメトキシ−5−イソプロピル−2,5−ジヒドロピラジン
1H NMR (CDCl3, 400 MHz):δ0.71 (3H, d, J = 6.7 Hz), 0.85 (3H, t, J = 7.3 Hz), 0.94-1.06 (1H, m), 1.11 (3H, d, J = 6.7 Hz), 1.12-1.30 (3H, m), 1.57-1.64 (1H, m), 1.74-1.84 (2H, m), 1.98 (1H, dt, J = 12.2, 4.9 Hz), 2.30-2.45 (3H, m), 3.70 (3H, s), 3.71 (3H, s), 3.95 (1H, d, J = 3.7 Hz), 7.00 (1H, d, J = 8.6 Hz), 7.25-7.29 (1H, m), 7.46 (1H, d, J = 1.8 Hz).
EIMS (+):456 [M]+
<参考例72>
(S)−4−(4−ブロモ−2−クロロフェニル)−2−t−ブトキシカルボニルアミノ−2−プロピル酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 0.89 (3H, t, J = 7.3 Hz). 0.96-1.10 (1H, m), 1.25-1.39 (1H, m), 1.46 (9H, s), 1.69 (1H, ddd, J = 13.9, 11.5. 4.8 Hz), 1.99-2.10 (1H, m), 2.20-2.35 (1H, m), 2.42 (1H, ddd, J = 13.9, 11.5, 4.8 Hz), 2.49-2.60 (1H, m), 2.64 (1H, td, J = 13.9, 4.8 Hz), 3.74 (3H, s), 5.62 (1H, br s), 7.03 (1H, d, J = 8.5 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.48 (1H, J = 1.8 Hz).
ESIMS (+) : 448 [M+H] +.
<参考例73>
(S)−4−(4−ブロモ−2−クロロフェニル)−2−t−ブトキシカルボニルアミノ−2−ブチル酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 0.87 (3H, t, J = 6.7 Hz), 0.95-1.02 (1H, m), 1.22-1.32 (3H, m), 1.46 (9H, s), 1.65-1.75 (1H, m), 2.00-2.10 (1H, m), 2.22-2.34 (1H, m), 2.38-2.48 (1H, m), 2.50-2.70 (2H, m), 3.75 (3H, s), 5.62 (1H, br), 7.02 (1H, d, J = 8.6 Hz), 7.28 (1H, dd, J = 8.6, 2.4 Hz), 7.47 (1H, d, J = 2.4 Hz).
ESIMS (+) : 462 [M+H] +.
<参考例74>
(S)−2−[2−(4−ブロモ−2−クロロフェニル)エチル]−2−t−ブトキシカルボニルアミノペンタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.29-1.42 (2H, m), 1.44 (9H, s), 1.53-1.62 (2H, m), 1.81 (1H, ddd, J = 13.9, 11.5, 5.4 Hz), 1.93 (1H, ddd, J = 13.9, 11.5, 5.4 Hz), 2.59-2.75 (2H, m), 3.73 (2H, d, J = 6.7 Hz), 4.15 (1H, br s), 4.62 (1H, br s), 7.11 (1H, d, J = 7.9 Hz), 7.31 (1H, dd, J = 7.9, 1.8 Hz), 7.49 (1H, d, J = 1.8 Hz).
ESIMS (+) : 420 [M+H] +.
<参考例75>
(S)−2−[2−(4−ブロモ−2−クロロフェニル)エチル]−2−t−ブトキシカルボニルアミノヘキサン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.93 (3H, t, J =7.3 Hz), 1.30-1.40 (4H, m), 1.44 (9H, s), 1.58-1.62 (2H, m), 1.78-1.86 (1H, m), 1.88-1.94 (1H, m), 2.60-2.72 (2H, m), 3.73 (2H, d, J = 6.2 Hz), 4.13 (1H, br), 4.62 (1H, br), 7.10 (1H, d, J = 8.6 Hz), 7.31 (1H, dd, J = 8.6, 2.4 Hz), 7.49 (1H, d, J = 2.4 Hz).
ESIMS (+) : 434 [M+H] +.
<参考例76>
5−t−ブチル−2−(メトキシメトキシ)ベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ1.27 (9H, s), 3.51 (3H, s), 3.78 (1H, br), 5.22 (2H, s), 7.01 (1H, d, J = 8.6 Hz), 7.09 (1H, dd, J = 8.6, 1.8 Hz), 7.26 (1H, d, J = 1.8 Hz).
EIMS (+) : 226 [M] +.
<参考例77>
2−(メトキシメトキシ)−5−フェニルベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ3.53 (3H, s), 3.86 (1H, s), 5.29 (2H, s), 7.15 (1H, d, J = 8.6 Hz), 7.27-7.38 (2H, m), 7.39-7.45 (2H, m), 7.48-7.56 (3H, m).
EIMS (+) : 246 [M] +.
<参考例78>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−プロピルフェニルチオ)フェニル]−2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.90 (3H, t, J = 7.3 Hz), 0.95 (3H, t, J = 7.3 Hz), 1.30-1.40 (2H, m), 1.44 (9H, s), 1.55-1.60 (2H, m), 1.74-1.84 (2H, m), 1.88-1.94 (2H, m), 2.48 (2H, t, J = 7.3 Hz), 2.60-2.70 (2H, m), 3.39 (3H, s), 3.73 (2H, d, J = 6.1 Hz), 4.16 (1H, br), 4.62 (1H, br), 5.16 (2H, s), 7.05-7.08 (3H, m), 7.09-7.10 (1H, m), 7.11-7.13 (1H, m), 7.22-7.24 (1H, m).
ESIMS (+) : 552 [M+H] +.
<参考例79>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−イソプロピルフェニルチオ)フェニル]−2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.18 (6H, d, J = 6.7 Hz), 1.30-1.40 (2H, m), 1.44 (9H, s), 1.45-1.60 (2H, m), 1.75-1.83 (1H, m), 1.86-1.95 (1H, m), 2.59-2.71 (2H, m), 2.82 (1H, sept, J = 6.7 Hz), 3.39 (3H, s), 3.70-3.72 (2H, m), 4.19 (1H, br), 4.63 (1H, br), 5.16 (2H, s), 7.08-7.16 (5H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+) : 552 [M+H] +.
<参考例80>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シクロプロピル−2−メトキシメトキシフェニルチオ)フェニル]−2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.55-0.60 (2H, m), 0.85-0.92 (2H, m), 0.95 (3H, t, J = 7.3 Hz), 1.30-1.40 (2H, m), 1.44 (9H, s), 1.52-1.60 (2H, m), 1.72-1.85 (2H, m), 1.91 (1H, dt, J = 11.6, 5.5 Hz), 2.60-2.75 (2H, m), 3.38 (3H, s), 3.73 (2H, d, J = 6.1 Hz), 4.18 (1H, br), 4.63 (1H, br), 5.15 (2H, s), 6.96 (1H, dd, J = 8.6, 2.4 Hz), 6.99 (1H, d, J = 2.4 Hz), 7.02-7.12 (3H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+) : 550 [M+H] +.
<参考例81>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−t−ブチル−2−メトキシメトキシフェニルチオ)フェニル]−2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.26 (9H, s), 1.28-1.40 (2H, m), 1.43 (9H, s), 1.50-1.61 (2H, m), 1.72-1.82 (1H, m), 1.84-1.96 (1H, m), 2.58-2.72 (2H, m), 3.38 (3H, s), 3.72 (2H, d, J = 6.7 Hz), 4.18 (1H, br), 4.62 (1H, br), 5.16 (2H, s), 7.06 (1H, dd, J = 8.6, 1.8 Hz), 7.07-7.14 (2H, m), 7.21 (1H, d, J = 1.8 Hz), 7.30 (1H, dd, J = 8.6, 3.0 Hz), 7.33 (1H, d, J = 3.0 Hz).
ESIMS (+) : 566 [M+H] +.
<参考例82>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−ビフェニルチオ)フェニル]−2−プロピルブタン−1−オール
1H NMR
(CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.28-1.40 (2H, m), 1.43 (9H, s), 1.54-1.62 (2H, m), 1.75-1.85 (1H, m), 1.88-1.96 (1H, m), 2.60-2.74 (2H, m), 3.42 (3H, s), 3.72 (2H, d, J = 6.1 Hz), 4.16 (1H, br), 4.62 (1H, br), 5.24 (2H, s), 7.14-7.16 (2H, m), 7.22 (1H, d, J = 8.6 Hz), 7.28-7.34 (2H, m), 7.34-7.42 (2H, m), 7.44-7.50 (4H, m) .
ESIMS (+) : 586 [M+H] +.
<参考例83>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.20-1.40 (2H, m), 1.43 (9H, s), 1.52-1.58 (2H, m), 1.72-1.94 (2H, m), 2.55-2.70 (2H, m), 3.71 (2H, d, J = 6.7 Hz), 4.15 (1H, br), 4.61 (1H, br), 5.00 (2H, s), 6.06 (1H, s), 6.89 (1H, dd, J = 8.5, 1.8 Hz), 6.99 (1H, d, J = 8.5 Hz), 7.02-7.07 (2H, m), 7.08-7.12 (2H, m), 7.30-7.42 (5H, m).
ESIMS (+) : 572 [M+H] +.
<参考例84>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−ブチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.94 (3H, t, J = 7.3 Hz), 1.20-1.40 (4H, m), 1.44 (9H, s), 1.57-1.62 (2H, m), 1.78-1.88 (1H, m), 1.90-2.00 (1H, m), 2.60-2.78 (2H, m), 3.74 (2H, d, J = 6.7 Hz), 3.92 (3H, s), 4.20 (1H, br), 4.63 (1H, br), 6.95 (1H, d, J = 8.6 Hz), 7.15-7.21 (2H, m), 7.31-7.35 (2H, m), 7.47-7.54 (1H, m).
ESIMS (+) : 562 [M+H] +.
<参考例85>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル] −2−ブチルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.93 (3H, t, J = 7.3 Hz), 1.20-1.40 (4H, m), 1.44 (9H, s), 1.54 (9H, s), 1.56-1.62 (2H, m), 1.77-1.87 (1H, m), 1.90-1.97 (1H, m), 2.60-2.80 (2H, m), 3.73 (2H, d, J = 6.1 Hz), 4.13 (1H, br), 4.62 (1H, br), 7.20 (2H, m), 7.30 (1H, d, J = 8.6 Hz), 7.39 (1H, s), 7.47 (1H, d, J = 1.8 Hz), 7.53 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 648 [M+H] +.
<参考例86>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−プロピルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.90 (3H, t, J = 7.3 Hz), 0.95 (3H, t, J = 7,3 Hz), 1.30-1.40 (2H, m), 1.43 (9H, s), 1.52-1.60 (2H, m), 1.61-1.71 (2H, m), 1.72-1.82 (1H, m), 1.85-2.05 (1H, m), 2.48 (2H, t, J = 7.3 Hz), 2.66 (2H, t, J = 8.6 Hz), 3.39 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.06-4.14 (1H, m), 4.23 (1H, dd, J = 10.3, 4.9 Hz), 4.50 (1H, br), 5.16 (2H, s), 7.06-7.12 (5H, m), 7.22 (1H, d, J = 1.8 Hz).
ESIMS (+) : 660 [M+H] +.
<参考例87>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−イソプロピルフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.2 Hz), 1.18 (6H, d, J = 6.8 Hz), 1.20-1.40 (4H, m), 1.44 (9H, s), 1.58-1.82 (2H, m), 2.66 (2H, t, J = 8.4 Hz), 2.82 (1H, sept, J = 6.8 Hz), 3.39 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.08-4.14 (1H, m), 4.20-4.26 (1H, m), 4.50 (1H, br), 5.16 (2H, s), 7.02-7.20 (5H, m), 7.23 (1H, d, J = 1.6 Hz).
ESIMS (+) : 660 [M+H] +.
<参考例88>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−シクロプロピル−2−メトキシメトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.55-0.60 (2H, m), 0.85-0.90 (2H, m), 0.95 (3H, t, J = 7.3 Hz), 1.30-1.40 (2H, m), 1.44 (9H, s), 1.54-1.68 (2H, m), 1.72-1.84 (2H, m), 1.95-2.05 (1H, m), 2.66 (2H, t, J = 8.6 Hz), 3.38 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.11 (1H, dd, J = 9.7, 4.9 Hz), 4.23 (1H, dd, J = 9.7, 4.9 Hz), 4.50 (1H, br), 5.14 (2H, s), 6.96 (1H, dd, J = 8.6, 2.4 Hz), 6.99 (1H, d, J = 2.4 Hz), 7.02-7.12 (3H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+) : 658 [M+H] +.
<参考例89>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(5−t−ブチル−2−メトキシメトキシフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.26 (9H, s), 1.30-1.40 (2H, m), 1.44 (9H, s), 1.60-1.80 (3H, m), 1.90-2.05 (1H, m), 2.62-2.76 (2H, m), 3.38 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.09-4.14 (1H, m), 4.23 (1H, dd, J = 9.8, 4.0 Hz), 4.49 (1H, br), 5.16 (2H, s), 7.05 (1H, dd, J = 8.0, 1.8 Hz), 7.08-7.12 (2H, m), 7.21 (1H, d, J = 1.8 Hz), 7.30 (1H, dd, J = 8.6, 2.4 Hz), 7.33 (1H, d, J = 2.4 Hz).
ESIMS (+) : 674 [M+H] +.
<参考例90>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−ビフェニルチオ)フェニル]−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.30-1.38 (2H, m), 1.43 (9H, m), 1.60-1.70 (2H, m), 1.72-1.82 (1H, m), 1.85-2.02 (1H, m), 2.62-2.72 (2H, m), 3.42 (3H, s), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.09-4.14 (1H, m), 4.20-4.28 (1H, m), 4.50 (1H, br), 5.23 (2H, s), 7.10-7.17 (2H, m), 7.20-7.25 (1H, m), 7.28-7.34 (2H, m), 7.36-7.43 (2H, m), 7.45-7.51 (4H, m).
ESIMS (+) : 694 [M+H] +.
<参考例91>
(S)−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−t−ブトキシカルボニルアミノ−1−ジメトキシホスホリルオキシ−2−プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.94 (3H, t, J = 7.3 Hz), 1.28-1.38 (2H, m), 1.43 (9H, s), 1.58-1.68 (2H, m), 1.72-1.82 (1H, m), 1.90-2.05 (1H, m), 2.58-2.68 (2H, m), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz), 4.02-4.12 (1H, m), 4.22 (1H, dd, J = 10.4, 5.5 Hz), 5.00 (2H, s), 6.07 (1H, s), 6.88 (1H, dd, J = 8.0, 2.4 Hz), 6.99 (1H, d, J = 8.0 Hz), 7.02-7.12 (4H, m), 7.30-7.38 (1H, m), 7.35-7.42 (4H, m).
ESIMS (+) : 680 [M+H] +.
<参考例92>
(S)−2−t−ブトキシカルボニルアミノ−4−[4−(2−t−ブトキシカルボニルオキシ−5−トリフルオロメチルフェニルチオ)−2−クロロフェニル]−1−ジメトキシホスホリルオキシ−2−ブチルブタン
1H NMR (CDCl3, 400 MHz): δ 0.93 (3H, t, J = 7.3 Hz), 1.27-1.40 (4H, m), 1.44 (9H, s), 1.54 (9H, s), 1.62-1.70 (2H, m), 1.77-1.84 (1H, m), 1.96-2.04 (1H, m), 2.64-2.74 (2H, m), 3.77 (3H, d, J = 11.0 Hz), 3.78 (3H, d, J = 11.0 Hz),4.08-4.14 (1H, m), 4.20-4.27 (1H, m), 7.19 (2H, m), 7.30 (1H, d, J = 8.6 Hz), 7.39 (1H, s), 7.47 (1H, d, J = 1.8 Hz), 7.53 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 756 [M+H] +.
旋光度:[α]D 26 -2.00 (c 0.51, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.82 (3H, t, J = 7.3 Hz), 0.88 (3H, t, J = 7.3 Hz), 1.20-1.35 (2H, m), 1.43-1.60 (4H, m), 1.64-1.76 (2H, m), 2.41 (2H, t, J = 7.3 Hz), 2.54-2.66 (2H, m), 3.65-3.85 (2H, m), 6.87 (1H, d, J = 8.6 Hz), 6.98-7.04 (2H, m), 7.05-7.09 (2H, m), 7.24 (1H, d, J = 8.6 Hz).
HRESIMS (+) : 488.1430 (C22H32ClNO5PSとして計算値 488.1427).
元素分析 : 実測値 C 52.49%, H 6.24%, N 2.79%, C22H31ClNO5PS. 0.75H2Oとして計算値 C 52.69%, H 6.53%, N 2.79%.
旋光度:[α]D 25 -2.08 (c 0.50, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.87 (3H, t, J = 7.3 Hz), 1.11 (6H, d, J = 6.7 Hz), 1.20-1.40 (2H, m), 1.45-1.60 (2H, m), 1.68 (2H, br), 2.59 (2H, br), 2.76 (1H, sept, J = 6.7 Hz), 3.70-3.82 (2H, m), 6.89 (1H, d, J = 8.4 Hz), 6.95-7.05 (2H, m), 7.10-7.15 (2H, m), 7.24 (1H, d, J = 8.4 Hz).
HRESIMS (+) : 488.1433 (C22H32ClNO5PSとして計算値 488.1427).
元素分析:実測値 C 51.93%, H 6.38%, N 2.69%, C22H31ClNO5PS. H2Oとして計算値 C 52.22%, H 6.18%, N 2.77%.
旋光度:[α]D 26 −1.68 (c 0.50, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.50-0.58 (2H, m), 0.80-0.87 (2H, m), 0.91 (3H, t, J = 7.4 Hz), 1.28-1.40 (2H, m), 1.50-1.63 (2H, m), 1.68-1.76 (2H, m), 1.78-1.88 (1H, m), 2.58-2.70 (2H, m), 3.70-3.84 (2H, m), 6.87 (1H, d, J = 8.4 Hz), 6.97 (1H, dd, J = 8.4, 1.8 Hz), 7.00-7.07 (3H, m), 7.28 (1H, d, J = 8.0 Hz).
HRESIMS (+):486.1276 (C22H30ClNO5PS として計算値 486.1271).
元素分析:実測値 C 52.06%, H 5.97%, N 2.64%, C22H29ClNO5PS. 1.2H2Oとして計算値 C 52.06%, H 5.76%, N 2.76%.
旋光度:[α]D 26 −1.94 (c 0.53, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.87 (3H, t, J = 7.3 Hz), 1.19 (9H, s), 1.20-1.35 (2H, m), 1.45-1.60 (2H, m), 1.62-1.74 (2H, m), 2.55-2.70 (2H, m), 3.60-3.85 (2H, m), 6.90 (1H, d, J = 8.6 Hz), 6.96-7.04 (2H, m), 7.22-7.30 (3H, m).
HRESIMS (+):502.1582 (C23H34ClNO5PS として計算値 502.1584).
元素分析:実測値 C 53.85%, H 6.44%, N 2.55%, C23H33ClNO5PS. 0.5H2Oとして計算値 C 54.06%, H 6.71%, N 2.74%.
旋光度:[α]D 26 −1.32 (c 0.50, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.86 (3H, t, J = 7.3 Hz), 1.20-1.35 (2H, m), 1.45-1.62 (2H, m), 1.64-1.76 (2H, m), 2.58-2.68 (2H, m), 3.68-3.80 (2H, m), 7.03-7.10 (2H, m), 7.13 (1H, d, J = 1.8 Hz), 7.22-7.30 (2H, m), 7.38 (2H, t, J = 8.0 Hz), 7.48-7.58 (4H, m).
HRESIMS (+):522.1275 (C25H30ClNO5PS として計算値 522.1271).
元素分析:実測値 C 56.58%, H 5.52%, N 2.38%, C25H29ClNO5PS. 0.5H2Oとして計算値 C 56.55%, H 5.69%, N 2.64%.
旋光度:[α]D 26 −2.15 (c 0.50, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.88 (3H, t, J =7.3 Hz), 1.22-1.38 (2H, m), 1.46-1.62 (2H, m), 1.66-1.80 (2H, m), 2.56-2.70 (2H, m), 3.70-3.82 (2H, m), 4.96 (2H, s), 6.80 (1H, d, J = 3.1 Hz), 6.85 (1H, d, J = 8.6 Hz), 6.90 (1H, dd, J = 8.6, 3.1 Hz), 7.07 (1H, dd, J = 8.0, 1.8 Hz), 7.11 (1H, d, J = 1.8 Hz), 7.24-7.38 (6H, m).
HRESIMS (+):552.1384 (C26H32ClNO6PS として計算値 552.1377).
元素分析:実測値 C 54.89%, H 5.53%, N 2.52%, C26H31ClNO6PS. H2Oとして計算値 C 54.78%, H 5.48%, N 2.46%.
旋光度:[α]D 26 −1.76 (c 0.50, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ0.86 (3H, t, J = 7.3 Hz), 1.20-1.32 (4H, m), 1.50-1.64 (2H, m), 1.68-1.80 (2H, m), 2.60-2.70 (2H, m), 3.70-3.80 (2H, m), 7.11 (2H, m), 7.22 (1H, d, J = 1.8 Hz), 7.30 (1H, d, J = 8.6 Hz), 7.40 (1H, d, J = 1.8 Hz), 7.52 (1H, dd, J = 8.6, 1.8Hz).
HRESIMS (+):528.0985 (C21H27ClF3NO5PS として計算値 528.0988).
元素分析:実測値 C 47.06%, H 4.92%, N 2.22%, C21H26ClF3NO5PS. 1/2H2Oとして計算値 C 46.98%, H 5.07%, N 2.61%.
旋光度:[α]D 25 −5.00 (c 0.10, DMSO).
1H NMR (DMSO-d6, 400 MHz):δ0.87 (3H, t, J = 6.7 Hz), 1.30 (2H, br), 1.53 (2H, br), 1.68 (2H, br), 2.62 (2H, br), 3.70-3.75 (2H, m), 6.90 (1H, d, J = 8.0 Hz), 7.02-7.06 (1H, m), 7.15 (1H, d, J = 1.8 Hz), 7.26 (1H, d, J = 8.6 Hz), 7.65-7.72 (2H, m).
HRESIMS (+):490.0857 (C20H26ClNO7PS として計算値 490.0856).
元素分析:実測値 C 44.94%, H 4.89%, N 2.51%, C20H25ClNO7PS. 0.7NaClとして計算値 C 45.25%, H 4.75%, N 2.64%.
<参考例93>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシ−5−トリフルオロメチルフェニルチオ)フェニル] −2−プロピルブタン−1−オール
1H NMR
(CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.29-1.43 (2H, m), 1.44 (9H, s), 1.59 (2H, dd, J = 7.3, 1.8 Hz), 1.83 (1H, ddd. J = 13.9, 12.1, 5.4 Hz), 1.96 (1H, ddd, J = 13.9, 12.1, 5.4 Hz), 2.63-2.78 (2H, m), 3.75 (2H, d, J = 6.7 Hz), 3.92 (3H, s), 4.17 (1H, br s), 4.64 (1H, s), 6.96 (1H, d, J = 8.5 Hz), 7.17 (1H, dd, J = 8.5, 1.8 Hz), 7.17 (1H, d, J = 8.5 Hz), 7.32-7.35 (2H, m), 7.51 (1H, dd, J = 8.5, 1.8 Hz) .
ESIMS (+) :548 [M+H] +.
<参考例94>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル] −2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.28-1.41 (2H, m), 1.44 (9H, s), 1.59 (2H, dd, J = 7.3, 1.8 Hz), 1.79 (1H, ddd. J = 13.9, 11.6, 5.5 Hz), 1.90 (1H, ddd, J = 13.9, 11.6, 5.5 Hz), 2.57-2.72 (2H, m), 3.72 (2H, d, J = 6.7 Hz), 4.16 (1H, br s), 4.61 (1H, br s), 6.77 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 7.09 (1H, d, J = 1.8 Hz), 7.13 (1H, d, J = 7.9 Hz), 7.16 (1H, J = 7.9 Hz), 7.63 (1H, dd, J = 7.9, 1.8 Hz), 7.80 (1H, d, J = 1.8 Hz) .
ESIMS (+) :534 [M+H] +.
<参考例95>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル] −2−プロピルブタン−1−オール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.30-1.43 (2H, m), 1.44 (9H, s), 1.54-1.60 (2H, m), 1.82 (1H, ddd, J = 13.9, 12.1, 5.4 Hz), 1.94 (1H, ddd, J = 13.9, 12.1, 5.4 Hz), 2.63-2.78 (2H, m), 3.40 (3H, s), 3.74(2H, d, J = 3.0 Hz), 4.16(1H, br s)4.63 (1H, s), 5.25 (2H, s), 7.16-7.23 (3H, m), 7.36 (2H, dd, J = 8.5, 1.8 Hz), 7.47 (1H, dd, J = 8.5, 1.8 Hz).
ESIMS (+) : 578 [M+H] +.
<参考例96>
(S)−2−t−ブトキシカルボニルアミノ−4−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−プロピルブタン−1−アール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.30-1.43 (2H, m), 1.46 (9H, s), 1.53-1.64 (2H, m), 1.89-2.30 (2H, m), 2.56 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 2.65 (1H, ddd, J = 13.4, 12.2, 4.9 Hz), 3.41 (3H, s), 5.23 (1H, br s), 5.25 (2H, s), 7.12 (1H, d, J = 7.9 Hz), 7.19 (1H, dd, J = 7.9, 1.8 Hz), 7.22 (1H, d, J = 7.9 Hz), 7.31 (1H, d, J = 1.8 Hz), 7.38 (1H, d, J = 1.8 Hz), 7.48 (1H, dd, J = 7.9, 1.8 Hz), 9.34 (1H, s).
ESIMS (+) : 576 [M+H] +.
<参考例97>
(S)−3−t−ブトキシカルボニルアミノ−5−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−3−プロピル−1−ペンテニルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.30-1.44 (2H, m), 1.46 (9H, s), 1.52-1.65 (2H, m), 1.92 (1H, td, J = 12.2, 4.9 Hz), 2.02-2.16 (1H, m), 2.62-2.80 (2H, m), 3.41 (3H, s), 3.72 (6H, d, J = 11.0 Hz), 4.63 (1H, br s), 5.22 (2H, s), 5.73 (1H, t, J = 17.7 Hz), 6.81 (1H, dd, J = 22.6, 17.7 Hz), 7.16-7.19 (2H, m), 7.22 (1H, d, J = 8.6 Hz), 7.35 (1H, d, J = 1.8 Hz), 7.36 (1H, d, J = 1.8 Hz), 7.50 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 682 [M+H] +.
<参考例98>
(S)−3−t−ブトキシカルボニルアミノ−5−[2−クロロ−4−(2−メトキシメトキシ−5−トリフルオロメチルフェニルチオ)フェニル]−3−プロピルペンチルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz): δ 0.95 (3H, t, J = 7.3 Hz), 1.26-1.40 (2H, m), 1.44 (9H, s), 1.52-1.65 (2H, m), 1.65-1.86 (4H, m), 2.04-2.28 (2H, m), 2.60-2.72 (2H, m), 3.41 (3H, s), 3.74 (6H, d, J = 11.0 Hz), 4.27 (1H, br s), 5.25 (2H, s), 7.10-7.28 (3H, m), 7.38-7.42 (2H, m), 7.52 (1H, dd, J = 7.9, 2.4 Hz).
ESIMS (+) : 684 [M+H] +.
旋光度:[α]D 25 -17.81 (c 0.10, MeOH).
1H NMR (DMSO-d6, 400 MHz) :δ 0.95 (3H, t, J = 7.3 Hz), 1.22-1.58 (6H, m), 1.64-1.86 (4H, m), 2.52-2.78 (2H, m), 7.09 (2H, d, J = 8.6 Hz), 7.23 (1H, s), 7.25-7.33 (1H, m), 7.41 (1H, s), 7.49 (1H, d, J = 8.6 Hz).
ESIMS (+) : 512 [M+H] +.
10%のウシ胎児血清、および300 μg/mLのGeneticinを含むHam’s F-12培地でヒトS1P3受容体発現CHO細胞を継代培養した。このヒトS1P3受容体発現CHO細胞を0.25% トリプシン処理後、ディッシュより回収し、10% ウシ胎児血清および300 μg/mLのGeneticinを含むHam’s F-12培地に浮遊した。その後、ヒトS1P3受容体発現CHO細胞が7 x 104 /100 μL/wellとなるように96 穴黒色クリアボトムプレート(BD Falcon Biocoat)に播種し、37℃、5 % CO2下で一晩培養した。翌日、100 μL 0.1 % 脂肪酸不含ウシ血清アルブミン (BSA)含有PBSで、wellを3回洗浄した。0.1 % BSA含有Ham’s F-12培地に交換後、37℃ CO2インキュベータで6時間血清飢餓処理を行った。
1時間のインキュベートの後、100 μL のHanks-HEPES バッファーで3回洗った。被験化合物 (125 nM、1.25 μM、12.5 μM)またはDMSOを溶解した同バッファーを100 μL加え、マイクロプレート蛍光分光光度計 (FLEX Station (Molecular Device社))中で37 ℃、30分インキュベートした。その後、同装置を用いて、段階希釈法にて終濃度の5倍濃度で作製したS1P (終濃度0.1 nM、1 nM、10 nM、100 nM、1 μM)を25 μL加え、カルシウム動員に基づくFluo3による蛍光を、励起波長485nm、検出波長525nmで検出、測定した。測定データに基づき、最大蛍光強度から最小蛍光強度を引いた値 (蛍光増加量)を算出した。測定した蛍光増加量を使用し、PRISM 4ソフトウェア (GraphPad)を用いて、S1Pの濃度と蛍光増加量の関係を曲線近似した。その結果に基づき、化合物未処理時および各濃度の化合物処理時におけるEC50値を各々算出した。これら数値をもとにSchild Plot解析を行い、解離定数Kd値を求めた。なお、1000 nmol/L>Kd値≧100 nmol/Lについては+、100 nmol/L>Kd値≧10 nmol/Lについては++、10 nmol/L>Kd値≧1 nmol/Lについては+++、1 nmol/L>Kd値については++++と表記し、表1に示した。
10%のウシ胎児血清、及び200 μg/mLのGeneticinを含むHam’s F-12培地で継代培養したヒトS1P受容体発現CHO細胞(hS1P1受容体発現CHO細胞、hS1P3受容体発現CHO細胞及びhS1P4受容体発現CHO細胞)を4×104 cells/wellで96穴黒色クリアボトム培養プレート(コースター)に播種し、37℃、5%CO2条件下で一晩培養した。さらにCa2+結合性蛍光指示薬としてCalcium Screening
Kit試薬(同仁化学)を添加し、37℃、5%CO2条件下で60分間培養した。培養後、マイクロプレート蛍光分光光度計(FLEX Station、モレキュラーデバイス)を用いて、励起波長485nm、検出波長525nmにおける蛍光強度を測定した。最終濃度の10倍の濃度になるよう培地で調製したS1P、あるいは被験化合物(最終DMSO濃度0.1%)を蛍光測定開始18秒後に添加し、1.5秒毎で添加後100秒まで蛍光強度を連続測定した。測定データに基づき、最大蛍光強度から最小蛍光強度を引いた値(蛍光増加量)を算出し、溶媒を添加したときの蛍光増加量とS1Pを10-6Mで作用させたときの蛍光増加量の差を100%として、被験化合物の蛍光増加率(%)を算出した。これを被験化合物の細胞内カルシウム動員誘導作用として、PRISMソフトウェア(GraphPad)を用いてEC50値を求めた。
非特許文献5(F.Nissen et al.,Nature,452,654(2008))に記載の方法を参考にして行った。C57BL/6Jマウス(チャールスリバー 雄7-8W)に、LPS (Lipopolysaccharide)が1mg/mlとなるように生理食塩水で溶解したものを、腹腔内投与(10ml/kg)した。被検化合物は10mg/kgでLPS投与15分前と2時間後に2回静脈内投与した。LPS投与18時間後に解剖し、腸間膜リンパ節と肺を摘出した。腸間膜リンパ節は200μl、肺は1mlの溶解バッファー(30mM Tris(pH7.4), 150mM NaCl, 0.1% TritonX-100, 2mM CaCl2, 2mM MgCl2)で溶解し、不溶物を遠心分離により除去した。IL-1β ELISA Kit(THERMO社)を用いて組織溶解液中のIL-1βを測定した。なお抑制率が50%以上の化合物は+++、50%>抑制率≧30%の化合物は++、30%>抑制率≧20%の化合物は+と表記し、表2に示した。
なお、抑制率は下記の計算式を用いて算出した。
本モデルは腸内細菌の漏出に伴う多微生物性の腹部敗血症モデルとして広く用いられるものである。非特許文献9(D.Rittirsch et al.,Nature Protocols,4,31(2009))に記載の方法を参考にして行った。
Long-Evansラット(日本エスエルシー 雄9W)を用いた。イソフルラン麻酔下でラットの腹部を切開し、盲腸を外に出した。盲腸を絹糸で結さつし、18G注射針を用いて盲腸先端部分に3箇所穴を開けた。処置後盲腸を体内に戻し、傷口を縫合した。その後ラットをケージに戻し、4日間観察し、生存率を求めた。被検化合物は大腿静脈に留置したカニューレより0.1 mg/kg/hrとなるようにCLP処置後2時間後から持続投与した。
実施例22の化合物の投与群は、媒体投与群に比べ生存曲線を右にシフトさせる作用(生存延長作用)が認められた。また、4日後の生存率も媒体群40%だったのに対し、実施例22の化合物では70%と生存率改善作用が認められた。本結果より、実施例22の化合物は敗血症に対し有効であることが示唆された。
Claims (12)
- 一般式(1)
[式(1)中、R1は水素原子、ハロゲン原子、トリフルオロメチル基、炭素数1〜6のアルキル基、炭素数3〜6のシクロアルキル基、炭素数6〜10のアリール基、炭素数1〜4のアルコキシ基、ベンジルオキシ基、炭素数1〜4のアシル基、シアノ基又はカルボキシル基を示し、R2 は炭素数1〜6のアルキル基又は炭素数2〜6のアルケニル基を示し、Xはメチレン基又は酸素原子を示し、Yは水素原子又は炭素数1〜6のアルキル基を示し、Zはハロゲン原子を示す]
で表されるジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 前記一般式(1)で表される化合物が、一般式(1a)
[式(1a)中、R1、R2、X、Yは前述の通り]
で表される請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 前記一般式(1)で表される化合物が、一般式(1b)
[式(1b)中、Xaは酸素原子又は−CH2−を示し、R1、R2、Yは前述の通り]で表される請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 前記一般式(1)で表される化合物が、一般式(1c)
[式(1c)中、R1及びR2は前述の通り]
で表される請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 前記R1がトリフルオロメチル基、炭素数1〜6のアルキル基、炭素数3〜6のシクロアルキル基、炭素数6〜10のアリール基又はベンジルオキシ基である請求項4記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。
- 前記一般式(1)で示される化合物が、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(R)−2−アリル−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−プロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[4−(5−t−ブチル−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステル、
(S)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−ビフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、又は
(S)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステルである請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 前記一般式(1)で示される化合物が、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アリル−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]ブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−トリフルオロメチルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−メチルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−プロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−イソプロピルフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(5−シクロプロピル−2−ヒドロキシフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[4−(5−t−ブチル−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステル、
(−)−2−アミノ−4−[2−クロロ−4−(2−ヒドロキシ−5−ビフェニルチオ)フェニル]−2−プロピルブチルリン酸モノエステル、又は
(−)−2−アミノ−4−[4−(5−ベンジルオキシ−2−ヒドロキシフェニルチオ)−2−クロロフェニル]−2−プロピルブチルリン酸モノエステルである請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。 - 請求項1〜7のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物を有効成分とするスフィンゴシン−1−リン酸3(S1P3)レセプターアンタゴニスト作用に基づく医薬。
- 気道収縮、気管支喘息、慢性閉塞性肺疾患(COPD)、肺気腫、気管狭窄症、びまん性汎細気管支炎、感染、結合組織病もしくは移植に伴う気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、敗血症、またはインフルエンザウイルスもしくはRSウイルス感染に基づくサイトカインストームの治療あるいは予防薬である請求項8記載の医薬。
- 動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症もしくは心筋梗塞、糸球体腎炎、血栓症、肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の治療薬である請求項8記載の医薬。
- 敗血症の治療又は予防薬である請求項8記載の医薬。
- 請求項1〜7のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物及び薬学的に許容されうる担体を含有する医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011521823A JP5616342B2 (ja) | 2009-07-09 | 2010-07-08 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009162289 | 2009-07-09 | ||
JP2009162289 | 2009-07-09 | ||
JP2010112138 | 2010-05-14 | ||
JP2010112138 | 2010-05-14 | ||
JP2011521823A JP5616342B2 (ja) | 2009-07-09 | 2010-07-08 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
PCT/JP2010/004453 WO2011004604A1 (ja) | 2009-07-09 | 2010-07-08 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011004604A1 JPWO2011004604A1 (ja) | 2012-12-20 |
JP5616342B2 true JP5616342B2 (ja) | 2014-10-29 |
Family
ID=43429031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011521823A Expired - Fee Related JP5616342B2 (ja) | 2009-07-09 | 2010-07-08 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8569270B2 (ja) |
EP (1) | EP2452944B1 (ja) |
JP (1) | JP5616342B2 (ja) |
KR (1) | KR20120089234A (ja) |
CN (1) | CN102471355B (ja) |
AU (1) | AU2010269668B2 (ja) |
BR (1) | BR112012000320A2 (ja) |
CA (1) | CA2764126A1 (ja) |
DK (1) | DK2452944T3 (ja) |
ES (1) | ES2514665T3 (ja) |
HK (1) | HK1171234A1 (ja) |
HR (1) | HRP20141065T1 (ja) |
MX (1) | MX2011013182A (ja) |
NZ (1) | NZ596605A (ja) |
PL (1) | PL2452944T3 (ja) |
PT (1) | PT2452944E (ja) |
SG (1) | SG176573A1 (ja) |
SI (1) | SI2452944T1 (ja) |
WO (1) | WO2011004604A1 (ja) |
ZA (1) | ZA201108459B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5795333B2 (ja) * | 2010-12-21 | 2015-10-14 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102863345A (zh) * | 2011-07-06 | 2013-01-09 | 中国医学科学院药物研究所 | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
WO2015194157A1 (ja) * | 2014-06-16 | 2015-12-23 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
CN110357773A (zh) * | 2019-07-08 | 2019-10-22 | 南通嘉禾化工有限公司 | 3-氯-4-羟基苯甲酸的合成 |
CN113754613B (zh) * | 2021-09-27 | 2023-06-30 | 北京工商大学 | 一种4-烯醇的苯硫基环醚化方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004074297A1 (ja) * | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
WO2008018427A1 (fr) * | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif |
JP2008239546A (ja) * | 2007-03-27 | 2008-10-09 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 |
JP2010013407A (ja) * | 2008-07-04 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体 |
JP2010077053A (ja) * | 2008-09-25 | 2010-04-08 | Kyorin Pharmaceut Co Ltd | フェノール誘導体及びそれらを有効成分とする医薬 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
ATE463478T1 (de) | 2001-09-27 | 2010-04-15 | Kyorin Seiyaku Kk | Diaryletherderivat, dessen additionssalz und immunosuppressivum |
EP1431284B1 (en) | 2001-09-27 | 2007-11-21 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
AU2003264430B2 (en) | 2002-09-19 | 2009-03-19 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
WO2005044780A1 (ja) | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤 |
JP2005247691A (ja) | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
MX2007006706A (es) | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
CN101282926B (zh) | 2005-10-12 | 2011-07-13 | 东亚荣养株式会社 | S1p3受体拮抗剂 |
EP2099768A2 (en) * | 2006-08-04 | 2009-09-16 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
-
2010
- 2010-07-08 DK DK10796915.6T patent/DK2452944T3/da active
- 2010-07-08 KR KR1020127003551A patent/KR20120089234A/ko active IP Right Grant
- 2010-07-08 EP EP10796915.6A patent/EP2452944B1/en active Active
- 2010-07-08 JP JP2011521823A patent/JP5616342B2/ja not_active Expired - Fee Related
- 2010-07-08 SG SG2011085511A patent/SG176573A1/en unknown
- 2010-07-08 BR BR112012000320A patent/BR112012000320A2/pt not_active IP Right Cessation
- 2010-07-08 ES ES10796915.6T patent/ES2514665T3/es active Active
- 2010-07-08 WO PCT/JP2010/004453 patent/WO2011004604A1/ja active Application Filing
- 2010-07-08 MX MX2011013182A patent/MX2011013182A/es active IP Right Grant
- 2010-07-08 CN CN201080030630.3A patent/CN102471355B/zh not_active Expired - Fee Related
- 2010-07-08 PL PL10796915T patent/PL2452944T3/pl unknown
- 2010-07-08 US US13/382,011 patent/US8569270B2/en active Active
- 2010-07-08 CA CA2764126A patent/CA2764126A1/en not_active Abandoned
- 2010-07-08 AU AU2010269668A patent/AU2010269668B2/en not_active Ceased
- 2010-07-08 SI SI201030811T patent/SI2452944T1/sl unknown
- 2010-07-08 NZ NZ596605A patent/NZ596605A/xx not_active IP Right Cessation
- 2010-07-08 PT PT107969156T patent/PT2452944E/pt unknown
-
2011
- 2011-11-17 ZA ZA2011/08459A patent/ZA201108459B/en unknown
-
2012
- 2012-11-21 HK HK12111884.2A patent/HK1171234A1/zh not_active IP Right Cessation
-
2014
- 2014-11-03 HR HRP20141065AT patent/HRP20141065T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004074297A1 (ja) * | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
WO2008018427A1 (fr) * | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif |
JP2008239546A (ja) * | 2007-03-27 | 2008-10-09 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤 |
JP2010013407A (ja) * | 2008-07-04 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体 |
JP2010077053A (ja) * | 2008-09-25 | 2010-04-08 | Kyorin Pharmaceut Co Ltd | フェノール誘導体及びそれらを有効成分とする医薬 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5795333B2 (ja) * | 2010-12-21 | 2015-10-14 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Also Published As
Publication number | Publication date |
---|---|
EP2452944A1 (en) | 2012-05-16 |
DK2452944T3 (da) | 2014-10-27 |
US20120101068A1 (en) | 2012-04-26 |
KR20120089234A (ko) | 2012-08-09 |
SI2452944T1 (sl) | 2015-01-30 |
EP2452944B1 (en) | 2014-09-10 |
AU2010269668A1 (en) | 2011-12-15 |
EP2452944A4 (en) | 2013-04-03 |
PL2452944T3 (pl) | 2015-03-31 |
NZ596605A (en) | 2013-09-27 |
JPWO2011004604A1 (ja) | 2012-12-20 |
US8569270B2 (en) | 2013-10-29 |
HK1171234A1 (zh) | 2013-03-22 |
MX2011013182A (es) | 2012-01-31 |
WO2011004604A1 (ja) | 2011-01-13 |
AU2010269668B2 (en) | 2013-12-19 |
CA2764126A1 (en) | 2011-01-13 |
PT2452944E (pt) | 2014-10-13 |
ES2514665T3 (es) | 2014-10-28 |
ZA201108459B (en) | 2012-07-25 |
BR112012000320A2 (pt) | 2016-03-22 |
HRP20141065T1 (hr) | 2015-02-13 |
SG176573A1 (en) | 2012-01-30 |
CN102471355A (zh) | 2012-05-23 |
CN102471355B (zh) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5188972B2 (ja) | アミノリン酸エステル誘導体及びそれらを有効成分とするs1p受容体調節剤 | |
JP5616342B2 (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP2007169194A (ja) | ジオキサフォスフォリナン誘導体とその付加塩及びスフィンゴシン−1−リン酸(s1p1,s1p4)受容体作動薬 | |
JP5795333B2 (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP2010077053A (ja) | フェノール誘導体及びそれらを有効成分とする医薬 | |
JP2011032226A (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP2010013407A (ja) | アミノアルコール誘導体 | |
JP2012131725A (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
PL233938B1 (pl) | Pochodne kwasu 3-fenylo-4-heksynowego jako agoniści GPR40 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140826 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140911 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5616342 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |